

David J. Moliterno, M.D.

General

Office Address

Division of Cardiovascular Medicine
University of Kentucky Medical Center
900 South Limestone Street
326A Charles T. Wethington Building
Lexington, KY 40536-0200
(859) 323-6694 voice
(859) 257-6060 fax
e-mail: Moliterno@uky.edu

Education

Undergraduate

College of Arts and Sciences
University of Michigan, Flint, Michigan
B.S. Honors, Biology, 1978-1982

Medical School

Medical College of Virginia
Virginia Commonwealth University, Richmond, Virginia
Doctor of Medicine, 1983-1987

Post Doctoral Training

Internship

Vanderbilt University Hospitals
Vanderbilt University Medical Center, Nashville, Tennessee
Intern in Internal Medicine, 1987-1988

Residency

Vanderbilt University Hospitals &
Nashville Veterans Affairs Medical Center
Vanderbilt University Medical Center, Nashville, Tennessee
Junior and Senior Resident in Internal Medicine, 1988-1990

Fellowships

Parkland Memorial Hospital &
Dallas Veterans Affairs Medical Center
University of Texas, Southwestern Medical Center, Dallas, Texas
Fellow in Cardiovascular Medicine, 1990-1993

Department of Internal Medicine
University of Texas, Southwestern Medical Center, Dallas, Texas
Research Training, Combined Fellowship Program
NIH T32 Research Fellow in Cardiovascular Medicine 1991-1992

Department of Cardiovascular Medicine
Section of Interventional Cardiology
The Cleveland Clinic Foundation, Cleveland, Ohio
Fellow in Interventional Cardiology, 1993-1994

Professional Activities

Faculty Appointments

Vice Dean/Vice President for Clinical Affairs
UK College of Medicine/UK HealthCare
University of Kentucky, 2014-2016

Senior Associate Dean for Clinical Affairs
College of Medicine
University of Kentucky, 2012-2014

Chairman, Department of Internal Medicine
Jack M. Gill Chair of Medicine
University of Kentucky, 2011-2021

Physician-In-Chief, Cardiovascular Service Line
University of Kentucky, 2009-2011

Professor of Medicine, Department of Internal Medicine
University of Kentucky, 2003-present

Vice-Chairman of Internal Medicine
University of Kentucky, 2004-2011

Jefferson Morris Gill Professor of Cardiology
University of Kentucky, 2003-2011

Chief, Division of Cardiovascular Medicine
University of Kentucky, 2003-2011

Medical Director, Gill Heart Institute
University of Kentucky, 2003-2011

Faculty Appointments (continued)

Staff Physician
Section of Interventional Cardiology
Department of Cardiovascular Medicine
The Cleveland Clinic Foundation
Cleveland, Ohio, 1994-2003

Medical Director, Angiographic Core Laboratory
Section of Cardiac Catheterization
Department of Cardiovascular Medicine
The Cleveland Clinic Foundation, 1994-2001

Associate Professor of Medicine
Department of Cardiovascular Medicine
Cleveland Clinic Health Sciences Center of Ohio State University
Cleveland, Ohio, 2000-2003

Medical Director, CIA
Cleveland Clinic Cardiology Investigators' Association
The Cleveland Clinic Foundation, 1999-2003

Staff Physician
Department of Cardiology
MetroHealth Medical Center
Cleveland, Ohio, 1995-2003

Assistant Professor of Medicine
Department of Cardiology
Cleveland Clinic Health Science Center of The Ohio State University
Cleveland, Ohio, 1994-1999

Accomplishments

Honors

Psi Chi - National Honor Society, 1982
Merck Scholastic Achievement Award, 1985
Bristol Cardiology Fellow Award, 1991
Syntex Cardiology Fellow Award, 1992
Life Member, *National Registry of Who's Who*
Listed in *Who's Who in Medicine and Healthcare*
Listed in *Who's Who in Science and Engineering*
Listed in *Who's Who in Medical Sciences Education*
Listed in *Best Physicians in America*
Cleveland Clinic International Physician-of-the-Year Award, 1999
Listed in *Guide to America's Top Physicians*, 2003
Included in *Best Doctors*, 2001-2020
Simon Dack Award *Journal of American College of Cardiology*, 2011
ACC-Kentucky Chapter, Lifetime Achievement Award, 2016

Certificates & Licensure

Advanced Cardiac Life Support
Board Certification in Internal Medicine (ABIM), 1991
Board Certification in Cardiovascular Medicine (ABIM), 1993
Board Certified in Interventional Cardiology (ABIM), 1999
Recertification in Cardiovascular Medicine (ABIM), 2003, 2013
Recertification in Interventional Cardiology (ABIM), 2009
State of Tennessee, medical license, 1988 (inactive)
State of Texas, medical license, 1990 (inactive)
State of Ohio, medical license, 1993 (inactive)
State of Kentucky, medical license, 2004-present

Academic Activities

Memberships

American College of Cardiology, Fellow (FACC)
American College of Physicians, Fellow (FACP)
European Society of Cardiology, Fellow (FESC)
Society for CV Angiography and Interventions, Fellow (FSCAI)
American Heart Association, Fellow (FAHA)
Atherosclerosis, Thrombosis, and Vascular Biology Council
American Medical Association
Association of Professors in Cardiology
Association of University Cardiologists

Frequent Journal Reviewer

American Heart Journal
American Journal of Cardiology
Annals of Internal Medicine
Circulation
Journal of the American College of Cardiology
Journal of the American Medical Association
Journal of the American Medical Association Cardiology
Journal of Thrombosis and Hemostasis
Journal of Thrombosis and Thrombolysis
Lancet
New England Journal of Medicine

Editorial Boards

Editor-in-Chief, CathSAP-3 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program), 2006-2010
Chief, *SAP* Editorial Board, 2007-2008
Editor-in-Chief, CathSAP-4 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program), 2010-2014
Associate Editor, *JACC-Cardiovascular Interventions*, 2006-2016
Editor-in-Chief, *JACC-Cardiovascular Interventions*, 2017-present
Guest Editor, *Circulation*, 2008-2016
Section Editor:
Journal of Thrombosis and Thrombolysis, 2003-2017
ACCSAP VI (Thrombosis), 2004

Editorial Boards (continued)

Board Member, *Cardiology Today's Intervention*, 2011-present

Medical Editor, *Cardiac Consult (Cleveland Clinic)*, 2001-2003

Editorial Consultant:

American Heart Journal, 2005-present

Cardiosource Clinical Trials, 2004-2006

Cardiovascular Revascularization Medicine, 2009-2010

Catheterization and Cardiovascular Interventions, 2006-present

Current Controlled Trials in Cardiovascular Medicine, 2002-2005

Journal of Interventional Cardiology, 2004-2017

Journal of the American College of Cardiology, 2001-2005

Journal of the American College of Cardiology, 2014-present

Leadership

American Board of Internal Medicine

Interventional Cardiology Examination Relevance Reviewer, 2005

American College of Cardiology Foundation

Strategic Education Directions Committee, 2004-2006

Political Action Committee Board, 2004-2007

Publications Committee, 2006-2009

Kentucky Chapter Governor-elect, 2006-2007

Kentucky Chapter Governor Board of Governors, 2007-2010

i2 Management Advisory Committee, 2008-2009

Task Force on Clinical Expert Consensus Documents, 2007-2013

Co-Chair, *i2* Annual Scientific Session, 2009-2010

Chair, *i2* Annual Scientific Session, 2010-2011

Interventional Scientific Council, 2012-2014

Clinical Policy Approval Committee (CPAC), 2016-present

Editorial Board Member: American College of Cardiology of Extended Learning (ACCEL), 2017-present

American Heart Association

Central Kentucky Chapter Board of Directors, 2004-2012

Arteriosclerosis and Thrombosis Council

Clinical Cardiology Council

European Society of Cardiology

Thrombosis Working Group, 2002-present

Leadership

University of Kentucky

Medical Center Advisory Board, 2004-2021

Clinical Directors Council, 2006-2021

University Faculty Senator, 2006-2010

Medical Center Clinical Sciences Area Committee, 2007-2010

Academic Organization & Structure Committee, 2007-2009

Search Committee, Dean for the College of Medicine, 2010-2011

Clinical Faculty Compensation Committee Leader, 2011-2016

Kentucky Medical Services Finance Committee, 2011-2020

Kentucky Medical Services Executive Committee, 2011-2021

UK HealthCare Finance and Capital Committee, 2011-2016

UK HealthCare Facilities Allocation Executive Committee, 2014-2017

Search Committee, Executive Vice President for Health Affairs, 2017

Beyond Blue Corporation, Board of Directors, 2016-2021

Executive Management Committee, 2017-2020

Ambulatory Oversight Committee, 2017-2021

Medical Group Committee, 2017 - 2021

Executive Quality & Safety Committee, 2017-2021

Hospital Operations Committee, 2019-2021

UK HealthCare Quality and Safety Committee, 2020-2021

Clinician Philanthropy Leadership Committee, 2020-2021

Federal Government

Cardiorenal Drug Advisory Council—U.S. Food and Drug
Administration (FDA), 2019-present

Past Principal Investigatorships and Committees

1. Clinical Events Committee: Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO II). CIBA-Geigy, Boehringer-Mannheim, Advanced Cardiovascular Systems.
2. Clinical Events Committee: A Randomized, Double-Blind, Comparative Safety and Efficacy Evaluation of Integrelin in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (IMPACT-AMI). COR Therapeutics.
3. Angiographic Core Laboratory Director: Evaluation of PTCA to Improve Long-term Outcomes by c7E3 Glycoprotein Receptor Blockade (EPILOG). Centocor, Eli Lilly.
4. Study Co-Principal Investigator: Prevention of Reocclusion and Inhibition of Thrombus and Myocardial Events (PRIME) Trial; A Randomized Trial of Efegatran Sulfate versus Heparin in Acute Myocardial Infarction. Eli Lilly.
5. Angiographic Core Laboratory Director: Reteplase versus Alteplase Investigation During Myocardial Infarction Trial (RAPID 2); Randomized, Double-blind Study Comparing the Efficacy of Double Bolus Reteplase to Accelerated tPA in Patients with Acute Myocardial Infarction. Boehringer Mannheim.
6. Study Co-Principal Investigator: Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study: A Randomized Double-Blind Phase II Trial Evaluating the Use of a GP IIb/IIIa Inhibitor, Lamifiban versus Placebo for Patients with Acute Myocardial Infarction. Hoffmann-LaRoche.
7. Study Principal Investigator: Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON); Randomized Double-Blind Trial to Evaluate the Use of GP IIb/IIIa Inhibitor, Lamifiban versus Placebo for Patients with Acute Coronary Syndromes. Hoffmann-LaRoche.
8. Chairman, Steering Committee: Global Unstable Angina Registry and Treatment Evaluation (GUARANTEE) Study: A Survey of Treatment Practice Patterns for Patients with Unstable Angina. Eli Lilly.
9. Angiographic Core Laboratory Director: Liposomal Intervention Followed by Thrombolysis (LIFT) Trial: A Phase II, Placebo-Controlled, Multi-center Study of TLC C-53 as an Adjunct to Thrombolytic Therapy in Patients with Acute Myocardial Infarction. The Liposome Company.
10. Study Co-Investigator: Gene Quest - Genetic Analysis of Complex Human Traits: Application to Premature Atherosclerotic Heart Disease. Millennium Pharmaceuticals.
11. Site Principal Investigator: Determinants of the Time of Myocardial Infarction Onset. Part II: Modifiers of Myocardial Infarction Onset. National Heart, Lung and Blood Institute of the National Institute of Health.
12. International Steering Committee: Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO III): A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction. Boehringer-Mannheim.
13. Angiographic Core Laboratory Director: ReoPro[®] in Acute Myocardial Infarction and Primary PTCA Organization and Randomized Trial (RAPPORT). Eli Lilly and Centocor.

14. Angiographic Core Laboratory Director: A Phase II Randomized, Open-Label Angiographic Trial Evaluating The Benefit of ReoPro® Bolus Plus 12-Hour Infusion With and Without Thrombolytic Therapy for Acute Myocardial Infarction (GUSTO-IV Pilot). Centocor and Eli Lilly.
15. Study Co-Principal Investigator: SYMPHONY: Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndromes. Genentech and Hoffmann-LaRoche.
16. Study Co-Principal Investigator: Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON-B); Phase III Randomized Double-Blind Trial to Evaluate the Use of Lamifiban versus Placebo for Patients with Acute Coronary Syndromes. Hoffmann-LaRoche.
17. Angiographic Core Laboratory Director: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial: A phase IV clinical trial of abciximab, intracoronary stent placement, or both in elective percutaneous coronary revascularization procedures. Centocor, Eli Lilly.
18. Study Co-Principal Investigator: The 2nd SYMPHONY: Sibrafiban (XubixTM) versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndromes: A randomized trial of chronic (1-year) administration of oral IIb/IIIa inhibition versus aspirin. Genentech and Hoffmann-LaRoche.
19. Angiographic Core Laboratory Director: Local Delivery of Heparin in Stenting for Sub-Optimal result or Threatened Closure Post-PTCA using the LocalMed Infusasleeve: a Multi-center Randomized Pilot Study (LIHPS). LocalMed.
20. Scientific Advisory Board Member, International Academy of Cardiology, Inc. and the 1st International Congress on Heart Disease, May 1999.
21. Angiographic Core Laboratory Director: Feasibility Study of the EndoTex Coiled Sheet Stent in the Treatment of Carotid Arterial Stenosis (ESCS-I). EndoTex Interventional Systems.
22. Site Principal Investigator: The Safety of Enoxaparin Therapy in Patients Undergoing Percutaneous Coronary Intervention and Receiving Concomitant Abciximab Therapy (NICE-4). Rhône-Poulenc Rorer Pharmaceuticals.
23. Steering Committee: The GOLD Study: a prospective, multi-center, observational study evaluating platelet function with Accumetrics Ultegra-Rapid Platelet Function Assay (RPFA) in patients undergoing coronary interventions using platelet glycoprotein IIb/IIIa inhibitors. Accumetrics, Inc.
24. Data Safety Monitoring Board: NICE-3 Study. Enoxaparin therapy in patients with unstable angina and non-Q-wave MI: safety of concomitant use of GP IIb/IIIa inhibitors. Aventis.
25. Study Chairman: Evaluation of the Rapidpoint Coag Monitor and the Low-Molecular-Weight Heparin (LMWH) Card. Cardiovascular Diagnostics, Inc.
27. Angiographic Core Laboratory Director: A Prospective, Randomized, Double Blind, Multi-Center Study Comparing the Effects of Atorvastatin versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Study. Parke-Davis Pharmaceutical Research and Pfizer Central Research.

28. Angiographic Core Laboratory Director: Norvasc[®] for Regression of Manifest Atherosclerotic Lesion by Intravascular Sonographic Evaluation (NORMALISE) Study. Pfizer US Pharmaceuticals.
 29. International Steering Committee: TARGET Study. Tirofiban or Abciximab for Reduction in Aggregation and Ischemic Events Trial. A multi-center international trial comparing tirofiban and abciximab for patients undergoing percutaneous myocardial revascularization. Merck Pharmaceuticals, Inc.
 30. XaNADU Data and Safety Monitoring Board. Xa Neutralization for Atherosclerotic Disease Understanding. Defining safe doses of DX-9065a when given with aspirin (325 mg/day) and to determine a pharmacodynamic dose-response relationship of DX-9065a and its relationship to a panel of biochemical coagulation markers in patients with coronary artery disease. Daiichi Pharmaceutical Co., Ltd.
 31. Study Principal Investigator: Evaluating Enoxaparin Clotting Times (ELECT Study). A multi-center trial assessing the Rapidpoint ENOX system among PCI patients receiving enoxaparin. PharmaNetics, Inc.
 32. Safety and Efficacy Monitoring Committee (SEMC) Advisory Member: The Perfusion by ThromboLytic and UltraSound (PLUS) trial. Timi3 Systems, Inc.
 33. Study Principal Investigator: Bivalirudin Anticoagulation Assessment During Coronary Interventions Study (BASIS). A multi-center PCI trial assessing ACT and ECT measurements among bivalirudin-treated patients. The Medicines Company and PharmaNetics, Inc.
 34. Steering Committee: Heparin-induced Thrombocytopenia Registry. Complications After Thrombocytopenia Caused by Heparin (CATCH). A multi-center, national registry of assessing the prevalence, treatment and outcome of patients with heparin-induced thrombocytopenia. Berlex Laboratories.
 35. International Steering Committee: Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI): A randomized, placebo-controlled study of pexelizumab among patients undergoing direct angioplasty for ST-elevation myocardial infarction. Proctor and Gamble Pharmaceuticals and Alexion Pharmaceuticals.
 36. Study Principal Investigator: Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin Study (TENACITY): A randomized, multi-center, double-blind, abciximab-controlled study to evaluate the efficacy of tirofiban versus abciximab among subjects undergoing percutaneous coronary intervention with stent placement receiving bivalirudin or heparin. Guilford Pharmaceuticals.
 37. Data Safety Monitoring Board: Randomized Evaluation of Stem Cells Mobilized to Recover and Enhance Myocardial Function after Acute Myocardial Infarction (RECOVER). The Cleveland Clinic Foundation.
 38. Data Safety Monitoring Board: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de novo Native Coronary Artery Lesions (SPIRIT III). Axio Research Company, Guidant Corporation.
 39. Data Safety Monitoring Committee: A multi-center, single-arm, registry study of the Taxus Liberté stent for the treatment of patients with de novo coronary artery lesions (TAXUS ATLAS). Boston Scientific, Inc.
-

40. Executive Committee: A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention (TRANSCENDENCE-PCI). Schering-Plough Research Institute.
41. Data Safety Monitoring Committee: Percutaneous Ventricular Restoration in Chronic Heart Failure Patients (PARACHUTE). Duke Clinical Research Institute, Duke University Medical Center.
42. Data Safety Monitoring Committee: Effect of Reconstituted High-Density Lipoprotein on Atherosclerosis – Safety and Efficacy (ERASE-MI). Montreal Heart Institute.
43. Data Safety Monitoring Board Chairman: A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y₁₂ Inhibitor, in Non-Urgent PCI (INNOVATE-PCI). Portola Pharmaceuticals.
44. Data Safety Monitoring Board: Immunomodulatory, Inflammatory, and Vasoregulatory Properties of Transfused Red Blood Cells as a Function of Storage. National Heart, Lung, Blood Institute (NHLBI) of National Institute of Health (NIH).
45. Data Safety Monitoring Committee: A multi-center, single-arm, registry study of the Taxus Liberté stent for the treatment of patients with de novo coronary artery lesions (PERSEUS). Boston Scientific, Inc.
46. International Steering Committee: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P-TIMI 50). Brigham and Women's Hospital and Schering-Plough Research Institute.
47. Executive Committee: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndromes (TRACER). Schering Plough Research Institute.
48. Data Safety Monitoring Board: Data Safety Monitoring Committee: Trans-apical ACURATE TA™ first-in-man Clinical Study of TAVR. Symetis.
49. Data Safety Monitoring Committee: A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects with Acute Coronary Syndrome (GEMINI ACS). Janssen Pharmaceuticals.
50. Executive Committee Member: Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients (PARIS) Study: A Prospective Single-arm International Registry. Sanofi-Aventis and Bristol-Myers Squibb.
51. International Steering Committee: Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT). Astra-Zeneca Pharmaceuticals.
52. Independent Data Monitoring Committee Chair: Milvexian Trials' Program. Factor XI/XIa Inhibition Among Patients with Acute Coronary Syndromes, Atrial Fibrillation, or as Secondary Prevention of Stroke. Janssen Pharmaceuticals/ Bristol-Myers Squibb.

Mentored Interventional Cardiology Fellows and Current Positions

- | | |
|--|---|
| 1. Steven R. Steinhubl, MD (1996-1997)
Director, Digital Medicine
Scripps Translational Science Institute
La Jolla, CA | 9. Martin J. Quinn, MD, PhD (2000-2002)
Cardiology Consultant
University of Dublin
Dublin, Ireland |
| 2. Koon-Hou Mak, MBBS (1997-1998)
National Heart Center
Singapore | 10. Leslie Cho, MD (2001-2002)
Director, Women's Health
The Cleveland Clinic Foundation
Cleveland, Ohio |
| 3. Walter S. Tan, MD (1998-1999)
Assistant Professor, Medicine & Radiology
East Carolina University
Greenville, North Carolina | 11. Marco Roffi, MD (2001-2002)
Associate Professor of Medicine
University Hospital
Zurich, Switzerland |
| 4. Matthew T. Roe, MD (1998-1999)
Assistant Professor of Medicine
Duke University Medical Center
Durham, North Carolina | 12. Albert W. Chan, MD, MSc (2001-2002)
Royal Columbian Hospital
British Columbia, Canada |
| 5. Deepak L. Bhatt, MD (1999-2000)
Professor of Medicine
Harvard Medical School
Boston, Massachusetts | 13. Jacqueline Saw, MD (2002-2003)
Assistant Professor of Medicine
University of Vancouver
British Columbia, Canada |
| 6. Derek P. Chew, MBBS (1999-2000)
Director, Coronary Care Unit
Flinders University
Flinders, South Australia | 14. Ivan Casserly, MD (2002-2003)
Assistant Professor of Medicine
University of Colorado
Denver, Colorado |
| 7. Samir R. Kapadia, MD (1999-2000)
Professor of Medicine
Director, Cardiac Laboratory
The Cleveland Clinic Foundation
Cleveland, Ohio | 15. Alison Bailey, MD (2005-2007)
Associate Professor of Medicine
Director, Cardiac Rehabilitation
University of Kentucky
Lexington, Kentucky |
| 8. Debabrata Mukherjee, MD MS (2000-2001)
Professor of Medicine
Chairman of Internal Medicine
Texas Tech University Health Science Center
El Paso, Texas | 16. Ahmed Abdel-Latif, MD, PhD (2007-2009)
Associate Professor of Medicine
University of Kentucky
Lexington, Kentucky |

**Updating of this section stopped ~ 2012*

Visiting Professor and International Lectures (abridged)

1. September 1995
The Austrian Society of Cardiology and the Working Group on Coronary Circulation of the
European Society of Cardiology
Vienna, Austria
Definition and Specification of Coronary Lesions: Angiography and Beyond
2. September 1995
Ohio State University
Columbus, OH
Use of IIb/IIIa Platelet-Receptor Antagonists in Interventional Cardiology
3. December 1995
The George Washington University Medical School
Washington, D.C.
Platelet Integrins and Receptor Antagonists in Cardiovascular Medicine
4. January 1996
23rd Annual Scientific Meeting of Egyptian Society of Cardiology
Luxor, Egypt
Contemporary Percutaneous Revascularization: State of the Art
5. May 1996
Istituto di Ricovero e Cura a Carattere Scientifico
Como, Italy
Antithrombotic Therapy in Acute Coronary Syndromes: IIb/IIIa in AMI
6. October 1996
Scientific Experts Panel Advisory Meeting; Glaxo Pharmaceuticals
London, England
*Biologic Role and Potential Indications for Chronic Platelet IIb/IIIa
Antagonism in Cardiovascular Medicine*
7. December 1996
The Cardiac Center of Creighton University
Omaha, Nebraska
Anticoagulation: The Role of IIb/IIIa Platelet Inhibitors
8. January 1997
Georgia Heart Institute University Hospital
Augusta, Georgia
Contemporary Diagnosis & Therapy of Acute Myocardial Infarction
9. April 1997
61st Annual Scientific Meeting of Japanese Circulation Society
Tokyo, Japan
Mega-Studies In Ischemic Heart Disease: When Are Meta-Analyses Adequate?

10. June 1997
XIXth Annual Congress of the International Society on Thrombosis and Hemostasis
Florence, Italy
*Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists
Thrombolytic Therapy for Acute Myocardial Infarction*
 11. June 1997
The University of Texas & The Texas Heart Institute
Houston, Texas
Emerging Strategies in the Treatment of Acute Coronary Syndromes
 12. August 1997
XIXth Congress of the European Society of Cardiology
Stockholm, Sweden
Non-Cardiac Uses of ReoPro[®]: Cerebrovascular Interventions
 13. October 1997
The University of South Dakota
Sioux Falls, South Dakota
Strategies to Improve Myocardial Reperfusion in Acute Infarction
 14. December 1997
The Singapore Society of Cardiology
Singapore, Singapore
Antiplatelet and Antithrombin Therapies: The Next Generation
 15. May 1998
The University of Texas, Southwestern Medical Center
Dallas, Texas
Contemporary Strategies to Maximize Perfusion and Reperfusion in Acute Coronary Syndromes
 16. May 1998
Henry Ford Hospital
Detroit, Michigan
Current Antiplatelet and Antithrombin Therapies in Unstable Angina and Myocardial Infarction
 17. May 1998
The Philippine Heart Association 29th Annual Scientific Meeting
Manila, Philippines
The 2nd Annual Rodolfo Soto Visiting Professor Lecture: Confronting the Challenges of Acute Ischemic Syndromes
 18. June 1998
The 9th Annual Meeting of the Society for Vascular Medicine and Biology
San Diego, California
Antiplatelet Therapies in Cardiology and Vascular Medicine
 19. September 1998
The 2nd International Congress of the Polish Cardiac Society
Katowice, Poland
Clinical Application of IIb/IIIa Inhibitors in Acute Coronary Syndromes
-

20. October 1998
Scientific Experts Advisory Panel Meeting, Yamanouchi Pharmaceuticals
Amsterdam, The Netherlands
Broadening the Application of IIb/IIIa Inhibitors in Vascular Medicine
 21. October 1998
Annual Scientific Session of the American College of Emergency Physicians
San Diego, California
From Clinical Trials to Clinical Practice: What Have We Learned from the EPIC, EPILOG, CAPTURE, 4P Trials?
 22. January 1999
Bowman Gray School of Medicine, Wake Forest University
Winston-Salem, North Carolina
Contemporary Antiplatelet and Antithrombin Therapies in Acute Coronary Syndromes
 23. January 1999
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
New Options in Antiplatelet Therapies for Acute Coronary Syndromes
 24. March 1999
The University of Cincinnati School of Medicine
Cincinnati, Ohio
Tailoring Therapies of Acute Myocardial Infarction for Individual Patients
 25. April 1999
St. Michael's Hospital
Toronto, Canada
Antiplatelet Therapies in Contemporary Cardiovascular Medicine: The Evolution Continues
 26. April 1999
Sunnybrook and Women's College Health Science Centre
Toronto, Canada
Cardiovascular Medicine: The Year 2000 and Beyond
 27. April 1999
Montreal Heart Institute
Montreal, Canada
Tailoring Therapies of Acute Myocardial Infarction for Individual Patients
 28. April 1999
Hôpital du Sacré-Cœur de Montréal
Montreal, Canada
The New Antiplatelet Therapies in Ischemic Heart Disease
 29. May 1999
The Myocardial Infarction Club
Istanbul, Turkey
Acute Coronary Syndromes and the Use of GPIIb/IIIa Antagonists and Direct Thrombin Inhibitors
-

30. May 1999
The Endovascular Therapeutics Conference
Paris, France
The Implications of the EPISTENT Trial
31. June 1999
International Experts Advisory Panel on Direct Thrombin Inhibitors
Lisbon, Portugal
Tailoring Therapies of Acute Myocardial Infarction for Individual Patients
32. June 1999
Vanderbilt University Medical Center Cardiology Grand Rounds
Nashville, Tennessee
Why Platelet IIb/IIIa Inhibitors Don't Work
33. August 1999
XVIIth Congress of the International Society of Thrombosis and Hemostasis
Washington, D.C.
The Role of IIb/IIIa Inhibitors in Cardiovascular Medicine
34. August 1999
Argentinian-Interamerican Congress of Cardiology
Buenos Aires, Argentina
Role of LMWH and New Antithrombins
35. August 1999
Argentinian-Interamerican Congress of Cardiology
Buenos Aires, Argentina
Pharmacologic Reperfusion: How to Improve TIMI 3 Flow
36. September 1999
Society for Vascular Medicine and Biology: Transatlantic Vascular Medicine Meeting
Edinburgh, Scotland
Antiplatelet Therapy: What's on the Horizon in Antiplatelet Therapies-Y2K and Beyond?
37. September 1999
University of Edinburgh School of Medicine
Edinburgh, Scotland
Why Platelet IIb/IIIa Inhibitors Don't Work
38. October 1999
Portuguese International Meeting of Ischemic Heart Disease
Lisbon, Portugal
Unstable Angina in the New Millennium: Diagnosis, Treatments, and Outcomes
39. October 1999
Annual Scientific Session of the American College of Emergency Physicians
Las Vegas, Nevada
New Pharmacology for the Emergency Room Treatment of Acute Coronary Syndromes

40. January 2000
The 9th Live Demonstration Course in Cardiovascular Intervention
Singapore, Singapore
Advances in Myocardial Reperfusion
41. May 2000
South African Interventional Cardiology Society
Johannesburg, South Africa
Translating Clinical Trial Results into Clinical Practice: ACS and PCI
42. May 2000
Videoconference to Brazilian Society of Cardiology
Rio de Janeiro, Brazil
IIB/IIIA Use in Contemporary Cardiology
43. August 2000
The ACC/SCAI Board Review Course
San Francisco, California
Thrombolytic Therapy in Interventional Cardiology
44. August 2000
Council for Thrombosis and Platelets Symposium
European Society of Cardiology
Amsterdam, The Netherlands
Risk/benefit of Combining Antithrombotic Treatments Symposium
Combining Antithrombotics and Antiplatelets for Stent Placement
45. September 2000
GUSTO IV Canadian Investigators Meeting
Toronto, Ontario, Canada
Key Novel Developments in the Care of Patients with Acute Coronary Syndromes Since the Inception of GUSTO IV ACS and AMI
46. September 2000
The Principles and Practice of Peripheral and Carotid Intervention, 3rd Annual
The Cleveland Clinic Foundation
Cleveland, Ohio
Pharmacotherapy in Peripheral Intervention: Anticoagulation
47. September 2000
34th Convegno Cardiologia 2000
Milan, Italy
Spontaneous and Iatrogenic Embolization of the Atherosclerotic Plaque
48. October 2000
ACC/SCAI Interventional Cardiology Board Review Course
Atlanta, Georgia
Thrombolytic Therapy in Interventional Cardiology

49. October 2000
Annual Scientific Session of American College of Emergency Physicians
Philadelphia, Pennsylvania
Management of Acute Myocardial Infarction 2001: Combination Therapy
50. November 2000
Duke University Medical Center
Raleigh, North Carolina
TARGET & TACTICS: More Answers, More Questions, or Both?
51. December 2000
Baylor University Medical Center
Dallas, Texas
Contemporary Antiplatelet Therapy for Cardiovascular and Cerebrovascular Disease
52. December 2000
Polish Cardiac Society (via video teleconference)
Interventional Cardiology Workshop
Krakow, Poland
Prevention of Microvascular Embolization During PCI of Complex Coronary Lesions and Carotid Stenting
53. January 2001
Acute Coronary Syndromes Symposium – TAKKS-II
Antalya, Turkey
Should We Monitor the Anticoagulation During Percutaneous Coronary Interventions?
54. January 2001
Mayo Clinic
Rochester, MN
Update on GP IIb/IIIa Clinical Trials
55. February 2001
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
GUSTO-IV, TACTICS, TARGET: Putting Them in Perspective
56. February 2001
International Task Force on the Safety of LMWH in Conjunction with GPIIb/IIIa Receptor Antagonists
New York, NY
Monitoring the Extent of anticoagulation During PCI
57. April 2001
Multi-site video teleconference
Brazil
Results and Implications of the TARGET Trial

58. July 2001
VIIth Annual Congress - Society of Interventional Cardiology (SOLACI)
Cleveland Clinic Symposium - SOLACI
Mexico City, Mexico
Endovascular Therapy in the Diabetic Patient
The Intermediate Lesion: Physiologic Assessment in the Cath Lab
59. August 2001
New Insights into the Molecular Mechanisms and Management of Acute Coronary Syndromes
Northwestern University Medical School and Northwestern Memorial Hospital
Chicago, IL
Management of STEMI
60. September 2001
European Society of Cardiology – XXIII Congress
Stockholm, Sweden
Impact of Abciximab on Mortality in Acute Coronary Disease
61. September 2001
Breaking the Barriers in AMI
Montreal, Quebec
Late-Breaking Trial Results: GUSTO V and Other Combination-Therapy Trials
62. October 2001
Managing Acute Myocardial Infarction in Canada in 2001
The Canadian Heart Research Centre
Halifax, Nova Scotia
Rescue and Facilitated PCI. The Role of the Balloon in Canada
63. October 2001
New Concepts in Acute Coronary Syndromes: Beyond 2000
The Canadian Cardiovascular Society
Halifax, Nova Scotia
Striking the Balance for Percutaneous Coronary Interventions: Are There Any Limits?
64. October 2001
ACC/SCA&I Board Review in Interventional Cardiology
Atlanta, GA
Thrombolytics
65. November 2001
International Society for Heart and Lung Transplantation 3rd Fall Education Meeting
Mechanical Cardiac Support and Replacement II Symposium
Anaheim, CA
New and Emerging Strategies for Anticoagulation
66. November 2001
Baylor College of Medicine
Houston, TX
IIb/IIIa Inhibitors in Cardiology: Wheat and Chaff?

67. November 2001
St. Luke's Episcopal Hospital, Texas Heart Institute
Houston, TX
Interaction of Platelets, Thrombin, Endothelium...How Do We Monitor Today's Therapies?
*Coronary Intervention in the Patient with Diabetes: Selective Benefit of Platelet GP IIb/IIIa
Receptor Inhibitors and Mechanisms of Risk Reduction*
68. December 2001
2nd Interventional Cardiology Workshop "New frontiers in interventional cardiology" (videotaped)
Krakow, Poland
Facilitated PCI: The Optimal Approach in the Right Setting
69. December 2001
East Carolina State University
Clinical Cardiology Trials – What's Hot, What's Not
70. January 2002
Budnitz Visiting Professor
Division of Cardiology/Cardiovascular Thrombosis Research Center
University of Massachusetts Medical School
Worcester, MA
Combination Pharmacotherapies in Percutaneous Coronary Intervention
71. February 2002
Columbia University Hospital Grand Rounds
New York, NY
Treatment Modalities for Acute MI
72. February 2002
Mt. Sinai Medical Center
Miami Beach, FL
AMI 2002: Discovering Optimal Treatment Pathways in AMI
73. March 2002
University of Miami School of Medicine
Miami Beach, FL
Optimal Management of AMI, Evidence for Combination Therapy and Facilitated PCI
74. April 2002
Genetics in Heart Disease
AHA Asian Pacific Meeting
Waikiki, Hawaii
Genetics and Treatment of Premature CAD - Findings from GeneQuest
75. May 2002
Cardiology Symposium
Kayseri, Turkey
Anticoagulation and Antithrombotic Treatment in 2002

76. May 2002
Cardiology Symposium
Isparta, Turkey
Anticoagulation and Antithrombotic Treatment in 2002
77. May 2002
Turkish Acute Coronary Syndromes Symposium III
Istanbul, Turkey
Anticoagulation and Antithrombotic Treatment in 2002
78. August 2002
VIIIth Congress of the Latin American Society of Interventional Cardiology (SOLACI)
Lima, Peru
Iib/IIIa Rx in ACS – PCI Hitting the TARGET
Monitoring New Generation Anticoagulants: Beyond ACTs and PAUs
Bridging Upstream ACS Pharmacotherapies with the Cath Lab
79. September 2002
National Association of Inpatient Physicians (NAIP) 3rd Annual Midwest Regional Meeting
Cleveland, OH
Acute Coronary Syndromes
80. October 2002
XXIXth Argentine Congress of Cardiology
Buenos Aires, Argentina
ACS Without ST Elevation
Antithrombotic Strategies: Which, For Whom, and For How Long?
Management of Acute Coronary Syndromes Beyond 2002
81. October 2002
XXIIIrd National Congress of the Italian Society of Invasive Cardiology
Verona, Italy
Low-Molecular-Weight Heparin With and Without Iib/IIIa Inhibitors
82. October 2002
Scripps' Clinic 13th Annual Coronary Interventions Course
San Diego, California
Point-of-care Testing in the Cath Lab: What You Need to Know
Percutaneous Coronary Intervention with Iib/IIIa Inhibitors, LMWH, and Direct Thrombin Inhibitors: Treating Old Challenges with New Therapies. Which for Whom?
83. October 2002
University of California San Diego Grand Rounds
San Diego, California
Bridging Upstream and In-lab Anticoagulation for Acute Coronary Syndromes

84. December 2002
3rd Interventional Cardiology Workshop, New Frontiers in Interventional Cardiology
Krakow, Poland
Glycoprotein IIb/IIIa Blockers and Thienopyridines in Treatment of ACS-PCI
Rapid Assessment of low-molecular-weight heparin, DTI, and Antiplatelet Agents in the Cath Lab
 85. December 2002
University of Texas, Southwestern Medical Center Grand Rounds
Dallas, Texas
Monitoring Therapies in Cardiovascular Medicine: From Bench to Bedside
 86. February 2003
University of North Carolina School of Medicine Grand Rounds
Chapel Hill, North Carolina
Rapid Assessment of Heparins and Hirudins in ACS-PCI
 87. March 2003
Brown University Interventional Program
Providence, Rhode Island
IIb/IIIa Therapy in Treatment of ACS Patients
 88. March 2003
University of Rochester School of Medicine Grand Rounds
Rochester, New York
Managing Atherothrombosis: Implications of Recent Clinical Trials
 89. May 2003
Duke University Medical Center / University of North Carolina Medical Education Program
Durham, North Carolina
Advancements in Antiplatelet Therapy Long-Term Use
 90. May 2003
Penn State University, Milton S. Hershey Medical Center Grand Rounds
Hershey, Pennsylvania
Glycoprotein IIb/IIIa Inhibitors in the Era of Coronary Stent Implantation
 91. May 2003
American College of Cardiovascular Nursing
North Canton, Ohio
Optimizing Management Strategies for Patient with Unstable Angina or NSTEMI ACS
 92. June 2003
European Society of Cardiology
Working Group on Thrombosis
Florence, Italy
Lessons from Glycoprotein IIb/IIIa Antagonists With or Without Catheters
 93. July 2003
XIXth Congress, International Society on Thrombosis and Hemostasis
Birmingham, United Kingdom
-

94. July 2003
St. Luke's Hospital
Grand Rounds
Milwaukee, WI
Complementary Actions of GPIIb/IIIa Inhibition and Other Adjunctive Agents Used During PCI
 95. August 2003
American College of Cardiology Foundation
ACCF/SCAI Board Review Program
Atlanta, GA
Current Management of Unstable Ischemic Syndromes
 96. August 2003
European Society of Cardiology
Vienna, Austria
*With IIb/IIIa Receptor Antagonists;
Use of GPIIb/IIIa Blockers in Acute Coronary Syndrome Patients Treated with Clopidogrel*
 97. September 2003
St. Vincent Mercy Medical Center
Cardiology Today
Toledo, OH
GPIIb/IIIa Inhibition in the Era of Coronary Stent Implantation
 98. September 2003
Wright Patterson Air Force Base Medical Center
CME Program
Dayton, OH
Acute Coronary Syndromes: Improving the Quality of Care
 99. September 2003
Fairview Hospital
8th Annual Critical Care Education Days
Interventional Cardiology Update – A Bright Horizon
 100. October 2003
The Cleveland Clinic Foundation
4th Annual Intensive Review of Cardiology
Acute Coronary Syndromes: Incidence and Pathophysiology Continuum
 101. October 2003
University of Vermont Medical School
New England Catheterization Conference
Burlington, VT
Adjunctive Pharmacology for PCI
 102. October 2003
Lakewood Hospital
Grand Rounds
Lakewood, OH
GPIIb/IIIa Inhibition in the Era of Coronary Stent Implantation
-

103. October 2003
Jewish Hospital Heart & Lung Institute
Sixth Annual Joint Summit on Markers in Cardiology
Louisville, KY
Point-of-Care Anti-Thrombotic Testing in Patients with Acute Coronary Syndromes
104. November 2003
The Cleveland Clinic Foundation
Men's Health Summit
Cleveland, OH
Genetics: Patterns, Implications, and Future Directions
105. February 2004
51st Annual Advanced Postgraduate Course
American Diabetes Association
San Francisco, CA
Revascularization Strategies for Patients with Diabetes
106. September 2004
Robert Wood Johnson University Hospital
Secaucus, NJ
Current Controversies in Acute Coronary Syndromes
107. November 2004
Beth Israel Medical Center
New York, NY
Current Controversies in Acute Coronary Syndromes
108. April 2005
Mexican Society of Interventional Cardiology
Guadalajara, Mexico
Reperfusion Strategies During Acute Myocardial Infarction
Unstable Angina Treatment and NSTEMI
109. October 2005
Italian Society of Interventional Cardiology
Genoa, Italy
Optimal Antiplatelet Treatment in Elderly ACS patients Treated with an Early Invasive Strategy
110. December 2005
Virginia Commonwealth University
Reperfusion Strategies in Cardiovascular Disease
Pan-vascular Disease and Controversies in Cardiovascular Medicine
Clinical Trials Update: Diabetes, DES, and Polypharmacy
111. December 2005
6th Interventional Cardiology Workshop
Krakow, Poland
UFH, LMWH or Bivalirudin During PCI in NSTEMI Patients?

112. May 2006
Mexican Society of Interventional Cardiology
Guadalajara, Mexico
Drug-Eluting Stents for Patients with Diabetes
Future Antiplatelet and Anticoagulant Therapies
 113. May 2006
Antiplatelet Therapy Developments Meeting
Paris, France
Tirofiban at High Bolus Dose - A Review of Emerging Data
 114. September 2006
Oregon Health and Science University
Portland, OR
Anticoagulation in Cardiology—What's New
HIT—New Insights to an Old Disease
 115. September 2006
XXVIIth National Congress of the Italian Society of Invasive Cardiology (GISE)
Genoa, Italy
How to Minimize Periprocedural Risks in Diabetic Patients
 116. September 2006
World Congress of Cardiology (ESC)
Barcelona, Spain
Adenosine Diphosphate Antagonists, Pharmacology and Clinical Impacts
 117. February 2007
34th Egyptian Society of Cardiology
Cairo, Egypt
Contemporary Acute Management of STEMI
New Antithrombotics, Can They Replace Conventional?
The Role of Heart Attack Centers in the Community
 118. May 2007
Mexican Society of Interventional Cardiology
Guadalajara, Mexico
HIT—New Perspectives on an Old Disease
Platelet Thrombin Receptors (PAR) as a New Antiplatelet Target
 119. June 2007
Antithrombotic Therapy Update
Nice, France
New Antiplatelet Agents
Coagulation 2007: Sites of Action of New Inhibitors and Monitoring
 120. November 2007
Current Concepts in Cardiovascular Management
Buffalo, NY
Thin-Strut BMS versus Thick Strut DES—Close Enough?
Heparin-induced Thrombocytopenia—An Under-Recognized Foe
-

121. March 2008
Emory Practical Intervention Course
Atlanta, GA
Navigating PCI Pharmacotherapy
122. August 2008
2008 Cardiac Society of Australia and New Zealand
Adelaide, Australia
Implications of Bleeding Following PCI
Non-ST-Elevation ACT: Integrating New Therapies
123. August 2008
2nd Annual Australian and New Zealand Endovascular Therapies Meeting
Adelaide, Australia
Platelet Inhibition in PCI—Best Practice
124. August 2008
European Society of Cardiology
Munich, Germany
Thrombosis, Clotting Cascade, and Anticoagulant Agents
Anticoagulants: Clinical Trials, Therapeutic Recommendations
125. October 2008
52nd Annual Scientific Meeting of the Korean Society of Cardiology
Seoul, Korea
Dual Antiplatelet Therapy among Patients with Acute Coronary Syndromes and with Coronary Artery Stents – Defining Optimal Treatment
126. December 2008
9th Interventional Cardiology Workshop
Krakow, Poland
Antithrombotic Drugs (UFH, LMWH, DTI, Anti Xa): How to Choose Optimal Drug for Particular Patient?
Optimal Antiplatelet and Antithrombotic Therapy during PCI in Stable Angina and NSTEMI/ACS
Critical Review of the New ESC and ACC/AHA 2008 Guidelines for the Management of Patients with STEMI: U.S. Perspective
127. April 2009
8th Annual John Lewis Interventional Lecture
Baylor College of Medicine—Texas Heart Institute, Houston, Texas
PAR-1 and Next Generation Antiplatelet Therapies in Cardiovascular Medicine
128. June 2009
Antithrombotic Therapy Update
European Heart House, Nice, France
Cangrelor versus IIb/IIIa Inhibitors: An Update
Medical Therapy versus PCI for Chronic Stable Angina
Thrombin Receptor Antagonist: Anticoagulation with Bleeding in CAD

129. May 2010
4th Annual Best of ACC Scientific Sessions
Dehli-Lucknow-Nagpur, India
New Antithrombotic Strategies in ACS and PCI
Acute Coronary Syndromes — Update 2010
130. April 2011
2nd Saudi Heart Association-ACC Joint Meeting
Jeddah, Saudi Arabia
Highlights of i2 Summit 2011 Clinical Trials
Multivessel and Left Main CAD: PCI versus CABG—Which is Better?
131. April 2011
2nd Emirates Cardiac Society-ACC Joint Meeting
Dubai, United Arab Emirates
New Antithrombotic Agents In Acute Coronary Syndromes
Highlights of Interventional Clinical Trials
Left Main Angioplasty
New Advances in Cardiac Stents – Biodegradable and More
132. October 2011
22nd Great Wall International Congress of Cardiology
Beijing, China
Highlights of i2 Summit 2011 Clinical Trials
133. June 2012
Antithrombotic Therapy Update
European Heart House, Nice, France
Combining Different Treatment Options for Cath Lab Therapy in STEMI
New Antiplatelet Drugs: Cangrelor, Elinogrel, TRA, and Other Newcomers
Bivalirudin During Percutaneous Interventions in Acute Coronary Syndromes
134. November 2012
Cleveland Clinic Foundation Heart and Vascular Grand Rounds
Cleveland, Ohio
Platelet PAR-1 Antagonists: Too much, too late?
135. December 2012
Indian Cardiac Society – ACC Joint Meeting
Cardiology Today and Tomorrow
Dubai, United Arab Emirates
Selecting Appropriate Antithrombotic Therapy: the Role of Novel Anti-thrombotic Agents
Cardiogenic Shock
136. June 2013
Prague Intervention VII
Prague, Czech Republic
Cardiogenic Shock: Is there a Single Best Strategy?

137. September 2013
61st Japanese College of Cardiology Scientific Sessions
Kumamoto, Japan
How to treat coronary artery disease in people with diabetes
138. January 2016
6th American College of Cardiology in India Symposium
Mumbai, India
Comparing the ESC and AHA/ACC Guidelines for NSTEMI—Why the Differences?
139. January 2016
6th American College of Cardiology in India Symposium
Mumbai, India
Stenting Associated with Thrombotic and Bleeding Disorders: The Challenge of Antithrombotic Approaches
140. March 2016
Visiting Professor Series—University of Minnesota
Minneapolis, MN
A Strategic Approach to Patients with Atrial Fibrillation and Undergoing PCI Requiring Dual Antiplatelet Therapy
141. April 2016
Virginia Commonwealth University Cardiology Grand Rounds
Richmond, VA
Polypharmacy Anticoagulation—How High and Long is the Tightrope?
142. February 2017
Christiana Care Health System
Newark, DE
Polypharmacy Anticoagulation—How High and Long is the Tightrope?
143. February 2017
European Society of Cardiology – ETP Course
Nice, France
Intravenous antithrombotic agents: bivalirudin, fondaparinux, LMWH, glycoprotein IIb/IIIa inhibitors, cangrelor
Thrombin receptor antagonists and other new oral antiplatelet drugs
144. October 2017
GISE National Congress of the Italian Society of International Cardiology
Milan, Italy
How to write a scientific paper: my tips and tricks
MV Disease in DM: No way! We can treat only low-intermediate complexity patients (SYNTAX <33)
145. October 2017
CCC Live Cases – 100th Broadcast Session
Icahn School of Medicine at Mount Sinai
New York, NY
Interventional Cardiology in the Next Decade

146. November 2017
CBS2017 Left Main & Coronary Bifurcation Summit
Nanjing, China
Guidance for young authors and reviewers
40 years history of coronary artery intervention
Polypharmacy anticoagulation: how to decide best antithrombotic treatments with A Fib and DES
Complex lesions and complex patients: treatment guideline similarities and differences between North America and Europe
147. December 2017
New Frontiers in Interventional Cardiology (NFIC)
Krakow, Poland
DAPT Among Patients with VKA or NOAC Treatment
Should the Improved Results with NOACs (compared with VKA) Change the LAA Closure Decision?
40 Years of PCI: A Tribute to Andreas Grüntzig
148. January 2018
Korean Society of Interventional Cardiology (KSIC)
Seoul, Korea
The Top Interventional Papers Published in JACC and JACC-Cardiovascular Interventions in 2017
Where the Next 10 Years of Interventional Cardiology May Be Heading and Where Not
149. March 2018
China Interventional Therapeutics (CIT)
Suzhou, China
The Top Interventional Papers Published in JACC and JACC-Cardiovascular Interventions in 2017
150. April 2018
17th Annual John Lewis Interventional Lecture
Baylor College of Medicine—Texas Heart Institute, Houston, Texas
Hot Topics and Top JACC Interventional Cardiology Papers 2017
151. September 2018
23rd ASEAN Federation of Cardiology Congress
Bangkok, Thailand
2018 Late Breaking Clinical Trials
LMCAD—PCI vs CABG: 40 Years and Evolution Continues
152. October 2018
Korean Society of Cardiology (KSC)
Seoul, Korea
Expanding the Role of NOACs: Post PCI and Post TAVR?
153. October 2018
GISE National Congress of the Italian Society of International Cardiology
Milan, Italy
What to do if my paper is rejected?
-

154. February 2019
Anandi L. Sharma Visiting Professor of Cardiovascular Medicine
New York, NY
Polypharmacy anticoagulation in Interventional cardiology: more questions than answers.
155. February 2019
Visiting Professor – Washington University School of Medicine Grand Rounds
St. Louis, MO
Polypharmacy anticoagulation in Interventional cardiology: more questions than answers.
156. March 2019
China Interventional Therapeutics (CIT)
Beijing, China
From Concerns to Trends: LAAC Study Overview and Outlook
Top 2018 Interventional Papers Published in JACC and JACC: Cardiovascular Interventions
157. April 2019
The University of North Carolina at Chapel Hill Grand Rounds
Chapel Hill, NC
Complex Antithrombotic Cases in Cardiovascular Medicine
158. October 2019
GISE National Congress of the Italian Society of International Cardiology
Milan, Italy
159. October 2019
Case Western Reserve University Grand Rounds
Cleveland, OH
Antithrombotic Trial Update—2019 Guidelines for Best Practices
160. November 2019
CBS2019 Left Main & Coronary Bifurcation Summit
Nanjing, China
JACC-INTV Trials that Changed Clinical Practice
TWILIGHT Trial—How Less has Become More for Clinical Outcome
161. February 2020
Visiting Professor – Mount Sinai Heart Grand Rounds
New York, NY
Best of JACC: Cardiovascular Interventions 2019

Publications – Abstracts

1. Brogan WC, Lange RA, Kim AS, **Moliterno DJ**, Hillis LD. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. *Journal of the American College of Cardiology* 1991; 17:174A.
2. **Moliterno DJ**, Lange RA, Meidell RS, Willard JE, Leffert CC, Boerwinkle EA, Gerard RD, Hobbs HH, Hillis LD. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. *Circulation* 1992;86(Suppl I):803.
3. **Moliterno DJ**, Leffert CC, Lange RA, Willard JE, Boerwinkle EA, Hillis LD, Hobbs HH. Plasma lipoprotein(a) in black subjects with and without angiographic evidence of coronary atherosclerosis. *Circulation* 1992;86(Suppl I):337.
4. **Moliterno DJ**, Willard JE, Lange RA, Negus BH, Boehrer JD, Glamann DB, Landau C, Rossen JD, Winniford MD, Hillis LD. Potentiation of cocaine-induced coronary vasoconstriction by cigarette smoking. *Circulation* 1993;88(Suppl I):I-254.
5. Berkarp B, Nissen SE, De Franco AC, **Moliterno DJ**, Franco I, Raymond RE, Sutton J, Lincoff AM, Guyer S, Tuzcu EM. Intravascular ultrasound demonstrates marked differences in surface and lumen shape following interventional devices. *Circulation* 1994;90(Suppl I):I-58.
6. De Franco AC, Nissen SE, Tuzcu EM, Lefkovits J, **Moliterno DJ**, Guyer S, Ellis SG. Ultrasound plaque morphology predicts major dissections following stand-alone and adjunctive balloon angioplasty. *Circulation* 1994;90(Suppl I):I-59.
7. De Franco AC, Tuzcu EM, **Moliterno DJ**, Elliott JM, Berkarp B, Franco I, Raymond RE, Whitlow PL, Guyer S, Nissen SE. Overestimation of lumen size after coronary interventions: Implications for randomized trials of new devices. *Circulation* 1994;90(Suppl I):I-550.
8. De Franco AC, Tuzcu EM, **Moliterno DJ**, Guyer S, Elliott JM, Nissen SE. Do new interventional devices “facilitate” balloon angioplasty? Ultrasound evidence of no reduction in vessel recoil. *Circulation* 1994;90(Suppl I):I-58.
9. Goodhart DM, Nissen SE, De Franco AC, Guyer S, **Moliterno DJ**, Tuzcu EM. Diagnosis of angiographically elusive left main and ostial left anterior descending lesions by intravascular ultrasound. *Circulation* 1994;90(Suppl I):I-450.
10. **Moliterno DJ**, Califf RM, Anderson K, Sigmon KN, Aguirre F, Weisman HF, Topol EJ and EPIC Study Investigators. Activated clotting time is increased during coronary interventions with platelet IIb/IIIa antagonism: results from the EPIC trial. *Journal of the American College of Cardiology* 1994;23:106A.
11. **Moliterno DJ**, Sapp SK, Topol EJ. The paradoxical effect of thrombolytic therapy for unstable angina: meta-analysis. *Journal of the American College of Cardiology* 1994;23:288A.
12. **Moliterno DJ**, Stebbins A, Maynard C. The influence of race on efficacy and complications of thrombolytic therapy: results from the GUSTO trial. *Circulation* 1994;90(Suppl I):I-109.
13. Tuzcuu EM, Berkarp B, **Moliterno DJ**, Goormastic M, De Franco AC, Nissen SE. Can angiography reliably detect and quantify coronary calcification? A comparative intravascular ultrasound study. *Circulation* 1994;90(Suppl I):I-277.

14. De Franco AD, Tuzcu EM, **Moliterno DJ**, Raymond RE, Franco I, Guyer S, Ellis SG, Whitlow PL, Nissen SE. “Directional” coronary atherectomy removes atheroma more effectively from concentric than eccentric lesions: intravascular ultrasound predictors of lesion success. *Journal of the American College of Cardiology* 1995;25:137A.
 15. Lincoff AM, Tcheng JE, Ellis SG, **Moliterno DJ**, Kitt MM, Debowey D, Topol EJ for the IMPACT II Investigators. Randomized trial of platelet glycoprotein IIb/IIIa inhibition with Integrelin for prevention of restenosis following coronary intervention: the IMPACT II angiographic substudy. *Circulation* 1995;92:I-607.
 16. Mayer EL, Robinson K, Jacobsen DW, Tuzcu EM, De Franco AC, **Moliterno DJ**, Guyer S, Nissen SE. Low plasma homocysteine levels predict reduced atheroma burden in patients undergoing coronary interventions: evidence from coronary intravascular ultrasound. *Journal of the American College of Cardiology* 1995;25:81A.
 17. Migrino RQ, Ross AM, Miller DP, Goel JM, and **Moliterno DJ** for the GUSTO Investigators. Lack of circadian variation in thrombolytic efficacy: results from the GUSTO angiographic substudy. *Circulation* 1995;92:I-777.
 18. **Moliterno DJ**, Califf RM, Anderson K, Aguirre F, Weisman HF, Topol EJ and EPIC Study Investigators. Special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: results from the EPIC trial. *Journal of the American College of Cardiology* 1995;25:155A.
 19. **Moliterno DJ**, De Franco AD, Tuzcu EM, Ellis SG, Eccleston DS, Raymond RE, Whitlow PL, Nissen SE. Intravascular ultrasound evidence of significant oversizing of angioplasty balloons in female patients. *Journal of the American College of Cardiology* 1995;25:94A.
 20. **Moliterno DJ**, Granger C, Califf RM, Elliott JM, Stebbins A, Topol EJ for the GUSTO Investigators. Improved prognosis for heavyweight patients receiving thrombolysis in acute myocardial infarction—bigger is better: results from GUSTO. *Journal of the American College of Cardiology* 1995;25:232A.
 21. Tuzcu EM, De Franco AC, Mayer E, **Moliterno DJ**, Hobbs RE, Bott-Silverman C, Stewart RW, McCarthy PM, Nissen SE. Older donor age predicts increased risk for coronary vasculopathy in the year following transplantation: serial examination by intravascular ultrasound. *Journal of the American College of Cardiology* 1995;25:333A.
 22. Asher CR, Stebbins AL, Maynard CL, Ross AM, **Moliterno DJ** for the GUSTO Investigators. Long-term survival differences between African American and Caucasians following myocardial infarction: one-year follow-up data from the GUSTO-I trial. *Circulation* 1996;94:I-197.
 23. De Franco AC, Tuzcu EM, Ziada KM, Magyar WA, Shah N, **Moliterno DJ**, Whitlow PW, Franco I, Ellis SG, Nissen SE. Intravascular ultrasound evidence for balloon oversizing in diabetics: a factor in higher complication rates? *Journal of American College of Cardiology* 1996;27:180A.
 24. Emanuelsson H, Beatt K, Ardissino D, **Moliterno DJ** for the GUSTO Investigators. Effect of desirudin treatment on diabetic patients with acute coronary syndromes. *Circulation* 1996;94:I-611.
 25. Migrino RQ, Ross AM, Betriu A, Wilcox RG, Miller DP, **Moliterno DJ** for the GUSTO Investigators. Preinfarction angina is not associated with improved outcome after thrombolytic therapy for myocardial infarction: results from GUSTO-I. *Circulation* 1996;94:I-611.
-

26. **Moliterno DJ** for the PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON Study. *Circulation* 1996;94:I-553.
27. **Moliterno DJ**, Aguirre FV, Cannon CP, Every NP, Granger CB, Sapp SK, Booth JE, Fergusson JJ for the GUARANTEE Investigators: the Global Unstable Angina Registry and Treatment Evaluation (GUARANTEE) Study. *Circulation* 1996;94:I-195.
28. **Moliterno DJ**, Harrington RA, Krucoff MW, Armstrong PW, Van de Werf F, Kristinsson A, Hui W, Paraschos A, Bhapkar M, Rames A, Topol EJ for the PARADIGM Investigators. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM trial. *Circulation* 1996;94:I-553.
29. **Moliterno DJ**, Sgarbossa EB, Armstrong PW, Granger CB, Van de Werf F, Califf RM, Topol EJ for the GUSTO II Investigators. A major dichotomy in unstable angina outcome: ST depression versus T-wave inversion: GUSTO II results. *Journal of American College of Cardiology* 1996;27:182A.
30. Steinhubl SR, **Moliterno DJ**, Ellis SG. Creatine kinase elevations following intracoronary stenting: impact of current technique. *Circulation* 1996;94:I-332.
31. Steinhubl SR, **Moliterno DJ**, Teirstein PS, Guarneri EM, Aguirre FV, Ferguson JJ, Perin EC, Strickman NE, Keriakes D, Tchong JE, Ellis SG, Topol EJ. Stenting for acute myocardial infarction: the early United States multi-center experience. *Journal of American College of Cardiology* 1996;27:279A.
32. Alexander JH, Newby LK, **Moliterno DJ**, Bhapkar M, Van de Werf HD, White, Harrington RA, Topol EJ, Califf RM for the PARAGON Investigators. Relationship of outcomes to treatment with lamifiban in patients undergoing PTCA: analysis of PARAGON A. *Journal of American College of Cardiology* 1997; 29:409A.
33. Brener SJ, Barr LA, Burchenal J, Katz S, George BS, Jones AA, **Moliterno DJ**, Topol EJ. A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI. The RAPPORT trial. *Circulation* 1997;96:I-473.
34. Cannon CP, Ferguson JJ, Every N, Anderson HV, Aguirre FV, Granger CB, French WJ, Sapp S, Booth JE, **Moliterno DJ** for the GUARANTEE Investigators. "Hot" unstable angina: Is it worse than subacute unstable angina? Results from the GUARANTEE Registry. *Journal of American College of Cardiology* 1997;29:489A.
35. Cannon CP, **Moliterno DJ**, Every N, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Scirica BM, Sapp S, Booth JE, Ferguson JJ for the GUARANTEE Investigators. Implementation of the AHCPR guidelines for unstable angina in 1996: Unfortunate differences between men and women. Results from the multi-center GUARANTEE Registry. *Journal of the American College of Cardiology* 1997;29:217A.
36. Every NR, Cannon C, Granger C, **Moliterno DJ**, Aguirre F, French W, Talley JD, Booth J, Ferguson J for the GUARANTEE Investigators. The influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina. *Journal of the American College of Cardiology* 1997;29:310A.

37. Harrington RA, **Moliterno DJ**, Newby K, Armstrong PW, van de Werf F, Simes RJ, Rames A, Bhapkar M, Califf RM, Keech A, Topol EJ. Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non-ST segment elevation acute coronary syndrome. *Circulation* 1997;96:I-473.
38. Harrington RA, **Moliterno DJ**, Van de Werf F, Keech A, Kleiman N, Bhapkar M, Rames A, Peek M, Topol EJ, Califf RM, Armstrong PW for the PARAGON Investigators. Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban. *Journal of the American College of Cardiology* 1997;29:409A.
39. Harrington RA, Newby LK, **Moliterno DJ**, Bhapkar M, Armstrong PW, Simes RJ, White HD, Van de Werf F, Rames A, Topol EJ, Califf RM for the PARAGON Investigators. Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial. *Journal of the American College of Cardiology* 1997;29:410A.
40. Krucoff MW, Green CL, Trollinger KM, Maas A, **Moliterno DJ**, Harrington RA, O'Connor CM, Pope JE. Enhanced antiplatelet therapy is more important than choice of thrombolytic agent in treatment of myocardial infarction. *Circulation* 1997;96:I-474.
41. Krucoff MW, Harrington RA, **Moliterno DJ**, Green CL, Trollinger KM, Morgan CD, Burks J, Nygaard T, Pope JE, Topol EJ, Califf, RM for the PARADIGM Investigators. The paradigm for antiplatelet effect on continuous 12-lead ST-segment recovery in Acute MI. *Journal of the American College of Cardiology* 1997;29:185A.
42. Miller JM, Barsness GW, Leimberger JD, Gard J, Ohman EM, Glassman J, Brown DL, Bengtson JR, Marsh D, Carr K, **Moliterno DJ**. Direct thrombin inhibition with efegatran does not suppress heightened thrombin generation during thrombolysis for acute myocardial infarction. *Circulation* 1997; 96:I-534.
43. **Moliterno DJ**, Asher CA, Califf RM, Clark KA, Guerci AD, Topol EJ for the GUSTO-IIb Investigators. Less myocardial but more cerebral ischemia in African Americans than Caucasians with acute coronary syndromes: results from GUSTO-II. *Journal of the American College of Cardiology* 1997;29:131A.
44. **Moliterno DJ**, Harrington RA, Newby K, Bhapkar M, Emanuelsson H, Armstrong PW, Topol EJ. Pronounced reduction in long-term ischemic events with platelet IIb/IIIa antagonism among diabetics with unstable angina: PARAGON 6-month results. *Circulation* 1997;96:I-474.
45. **Moliterno DJ**, Topol EJ. Meta-analysis of platelet GP IIb/IIIa antagonist randomized clinical trials in ischemic heart disease: consistent, durable, salutary effects. *Circulation* 1997;96:I-475.
46. **Moliterno DJ**. Megastudies in ischemic heart disease: When are meta-analyses adequate? *Japanese Circulation Journal* 1997, 61: I-44.
47. Newby K, Harrington RA, Bhapkar M, Granger CB, Rames A, **Moliterno DJ**. Tight control of aPTT in acute coronary syndrome patients using an automated strategy for bedside heparin adjustment: results from the PARAGON A trial. *Circulation* 1997;96:I-748.

48. Barr LA, Brener SJ, Jones AA, **Moliterno DJ**, Effron MB, Topol EJ for the RAPPORT Investigators. Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. *Journal of the American College of Cardiology* 1998;31:237A.
49. Brener SJ, Barr LA, Cohen ED, White HJ, **Moliterno DJ**, Cheek HB, Effron MB, Topol EJ for the RAPPORT Investigators. Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. *Journal of the American College of Cardiology* 1998;31:54A.
50. Farias C, **Moliterno DJ**, Garcia MJ, Cardon L, Rodriguez L. Improvement in regional left ventricular function early after successful coronary angioplasty. A Doppler tissue echocardiographic study. *Circulation* 1998;98:I-23.
51. Farias CA, **Moliterno DJ**, Rodriguez L, Cardon L, Obadashian J, Thomas JD, Garcia MJ. Myocardial relaxation velocities are more sensitive than segmental contractility in detecting early ischemia during PTCA. Presented at the American Society of Echocardiography Meeting, 1998.
52. Lincoff AM, **Moliterno DJ**, Ellis SG, Debowey D, Cabot CF, Booth JE, Godfrey NK, Topol EJ. Six-month angiographic outcome with abciximab and stents: the EPISTENT angiographic substudy. *Circulation* 1998;98:I-768.
53. McErlean ES, DeLuca SA, Brown K, Broze-Ellert R, Apperson-Hansen C, Miller ML, **Moliterno DJ**, Topol EJ. Point-of-care testing for aPTT improves cost outcomes following coronary interventions. *Journal of the American College of Cardiology* 1998;31:49A.
54. Miller JM, Ohman EM, Schildcrout JS, **Moliterno DJ**, Hochman JS, Karnash SL, Califf RM. Hormone replacement therapy among post-menopausal women with acute myocardial infarction: Insights from GUSTO-III. *Circulation* 1998;98:I-8.
55. **Moliterno DJ**, Harrington RA, Newby KL, Armstrong PW, van de Werf F, White HD, Califf RM, Topol EJ. Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON Study 1-year follow-up. *Journal of the American College of Cardiology* 1998;31:208A.
56. Patel VB, Kapadia SR, Balog C, **Moliterno DJ**. Improved clinical and angiographic outcome with abciximab versus stents for patients with preprocedural TIMI-2 flow. *Circulation* 1998;98:I-294.
57. Roe MT, **Moliterno DJ**, Cannon CP, Every NR, Aguirre FV, Granger CB, Sapp S, Booth J, Ferguson JJ for the GUARANTEE Investigators. Improvements in the treatment of the elderly patients with unstable angina: results from the GUARANTEE Registry. *Journal of the American College of Cardiology* 1998;31:308A.
58. Smalling RW, Karlsberg RP, Weiner R, Ebersole DG, Thadani U, Bates E, Habib GB, **Moliterno DJ**, Park YC, Freitag JJ for the LIFT Investigators. Liposome combined with fibrinolysis for reperfusion without added oxidative injury in acute myocardial infarction. *Journal of the American College of Cardiology* 1998;31:411A.
59. Steiner B, Hofer U, Wittke B, Harrington RA, Bhapkar MV, Armstrong PW, **Moliterno DJ**. Plasma level of lamifiban and platelet receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A. *Circulation* 1998;98:I-561.

-
60. Steiner B, Hofer U, Wittke B, Topol EJ, Califf RM, Harrington RA, Armstrong PW, Van de Werf F, **Moliterno DJ**. Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A. *European Heart Journal* 1998;19:598.
 61. Steinhubl SR, Kottke-Marchant K, **Moliterno DJ**, Rosenthal ML, Topol EJ, Lincoff AM. Diabetics and nondiabetics achieve similar levels of platelet inhibition with abciximab therapy during and following percutaneous revascularization. *European Heart Journal* 1998;19:238.
 62. Steinhubl SR, Kottke-Marchant K, Rosenthal M, **Moliterno DJ**, Lincoff AM. Diabetics and non-diabetics achieve similar levels of platelet inhibition with abciximab therapy during and following percutaneous revascularization. *Circulation* 1998;98:I-767.
 63. Steinhubl SR, Lauer MS, Mukherjee DP, **Moliterno DJ**, Ellis SG, Topol EJ. Pretreatment with ticlopidine reduces non-Q-wave myocardial infarctions following intracoronary stenting. *Journal of the American College of Cardiology* 1998;31:100A.
 64. Bajzer CT, Whitlow PW, Lincoff AM, **Moliterno DJ**, Topol EJ, Ellis SG. Coronary perforation and pericardial tamponade risk in the abciximab era. *Journal of the American College of Cardiology* 1999;33:73A.
 65. Bhatt DL, Patel VB, Robbins MA, Wolski KE, **Moliterno DJ**, Ellis SG. Effect of coronary morphology and vessel size on the benefit of abciximab with stenting. *Circulation* 1999;100:I-857.
 66. Cura F, L'Allier PL, Tan WA, Wolsky KE, **Moliterno DJ**, Brener SJ. The benefit of glycoprotein IIb/IIIa inhibition for stenting is maximum in Non-BENESTENT/STRESS-like lesions. *Circulation* 1999;100:I-380.
 67. Farias C, **Moliterno DJ**, Garcia MJ, Rodriguez L, Odabashian JA, Morehead AJ, Thomas JT. Tissue doppler echocardiography detects improvement in regional diastolic function after angioplasty. *Circulation* 1999;100:I-727.
 68. Herrmann HC, **Moliterno DJ**, Bode C, Betriu A, Lincoff AM, Ohman EM. Combination abciximab and reduced-dose reteplase facilitates early PCI in acute MI: results from the SPEED trial. *Circulation* 1999;100:I-188.
 69. Kaul P, Fu Y, Chang W-C, Harrington R, **Moliterno DJ**, Van de Werf F, Armstrong PW. The ST depression ≥ 2 mm sign: an ominous prognosis in acute coronary syndromes. *Circulation* 1999;100:I-432.
 70. Patel VB, Gasler JP, Prosper D, **Moliterno DJ**. The optimal peak ACT during coronary intervention in the IIb/IIIa era. *Circulation* 1999;100:I-620.
 71. Patel VB, **Moliterno DJ**, Lincoff AM, Balog C, Ellis SG, Topol EJ. Which patients should receive abciximab in the contemporary stent era? *European Heart Journal* 1999;20:377
 72. Tan WA, Lincoff AM, Jia G, **Moliterno DJ**. A prediction model to determine the incremental value (death or MI) of stenting, abciximab, or both according to risk stratum. *Circulation* 1999;100:I-733.
-

73. Gassler JP, Silver MJ, **Moliterno DJ**, Lincoff AM, Ellis SG. Multivessel percutaneous coronary interventions during acute coronary syndromes appear to be safe in the IIb/IIIa antagonist era. *Journal of the American College of Cardiology* 2000;35:357A.
74. **Moliterno DJ**, Antman EM, Ohman M, Miller J, Marble SJ, Murphy S, Ivanc TB, Schuhwerk K, Gibson CM. Concordance Between Core Labs in Trial Results Using TIMI Flow Grades and Frame Counts. *Circulation* 2000;102:II-590.
75. Mukherjee D, Mahaffey K, Sparapani R, Dyke C, Roe M, **Moliterno DJ**, Harrington R, Berdan L, Topol E. The Promise of Combined LMW Heparin and Platelet Glycoprotein IIb/IIIa Inhibition: results from PARAGON B. *Circulation* 2000;102:II-591.
76. Mukherjee D, Reginelli J, **Moliterno DJ**, Yadav J, Schneider J, Raymond R, Whitlow P, Franco I, Ellis S. Mortality Reduction with Abciximab for In-stent Restenosis. *Circulation* 2000;102:II-666.
77. Steinhubl S, Talley D, Kereiakes D, Braden G, Tcheng J, Casterella P, **Moliterno DJ**, Berger P, Popma J, Dangas G, Gallo R, Navetta F, Sane D, Holmes D, Teirstein P, Topol EJ. A prospective multi-center study to assess the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention: the GOLD Study. *Journal of the American College of Cardiology* 2000;35:44A.
78. Steinhubl S, Talley D, Kereiakes DJ, Braden GA, Tcheng JE, Casterella PJ, **Moliterno DJ**, Berger PB, Topol EJ. The level of platelet inhibition maintained with a GPII/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE. Results of the GOLD Study. Submitted to the XXII Congress of the European Society of Cardiology (ESC), 2000. *European Heart Journal* 2000;21:145.
79. Steinhubl SR, Talley DJ, Kereiakes DJ, Braden GA, Jia G, Casterella, **Moliterno DJ**, Navetta FI, Berger PB, Gallo R. Presence of angiographically visible thrombus, but not clinical syndrome, is associated with lower levels of platelet inhibition with a GPIIb/IIIa inhibitor in patients undergoing a percutaneous coronary intervention. Results from the Gold Study. *Circulation* 2000;102:II-419.
80. Steinhubl SR, Talley JD, Kereiakes DJ, Braden GA, Tcheng JE, Casterella PJ, **Moliterno DJ**, Navetta FI, Berger PB, Popma JJ, Dangas G, Theroux P. Correlates of baseline platelet function as measured by the Ultegra-RPFA and its association with the level of platelet inhibition achieved with GPIIb/IIIa inhibitor therapy. Results from the Gold Study. *Circulation* 2000;102:II-418.
81. Topol E, **Moliterno DJ**, Rogers W, Newby LK, Bolk S, Daley G, Cannata R, Metivier J, McCarthy J. Genetic basis of premature coronary atherosclerosis and myocardial infarction: role of the thrombospondin genes. *Circulation* 2000;102:II-31.
82. Chan AW, Bhatt DL, Chew DP, Quinn MJ, **Moliterno DJ**, Topol EJ, Ellis SG. Stunning mortality benefit of HMG-CoA reductase inhibitors beginning early after percutaneous coronary intervention—results from 6,412 patients. *Canadian Journal of Cardiology* 2001;17:103C
83. Chan AW, Chew DP, Bhatt DL, **Moliterno DJ**, Ellis SG. Sustained mortality benefit for cardiogenic shock complicating acute MI—experience from an 8-year registry. *Canadian Journal of Cardiology* 2001;17:213C.

-
84. Chan AW, Chew DP, Bhatt DL, **Moliterno DJ**, Ellis SG. Sustained mortality benefit from combination of stents and abciximab for cardiogenic shock complicating acute MI-experience from an 8-year registry. *Circulation* 2001;104:II-386.
 85. Chan AW, Quinn MJ, Mukherjee D, **Moliterno DJ**, Ellis SG. Striking mortality benefit of β -blockade after successful elective percutaneous coronary intervention. *Circulation* 2001;104:II-711.
 86. Martin JL, Fry ETA, Serano A, Atherley TH, Ozoux ML, Guimart C, Chevalier P, Bigonzi F, Pensyl C, Sanderink GJ. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI Study. *European Heart Journal*, 2001;22:14.
 87. McGuire DK, Kristinsson A, Bhapkar MV, Aylward PE, Verheugt FWA, Weaver WD, **Moliterno DJ**, Newby LK. Early statin use after acute coronary syndromes (ACS) and outcomes at 90 days. *Circulation* 2001;104:II-343.
 88. McGuire DK, Newby LK, Bhapkar MV, **Moliterno DJ**, Ohman EM, Dougherty FC, Harrington RA, White HD, Van de Werf F, Califf RM, Topol EJ, the SYMPHONY Investigators. Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial. *Journal of the American College of Cardiology* 2001;37:372A.
 89. **Moliterno DJ**, Asher CA, Bhapkar MV, McGuire DK, East MA, Newby K. Increased risk of ischemic and hemorrhagic events among black patients receiving oral GP IIb/IIIa inhibitors: 1st and 2nd SYMPHONY trials. *Circulation* 2001;104:II-779.
 90. **Moliterno DJ**, Herrmann HC, Powers ER, Grines CL, Yakubov SJ, Cohen DJ, Parker HG, Frey MJ, Stone GW, Topol EJ for the TARGET Investigators. The effects of tirofiban versus abciximab among diabetic patients undergoing stent placement: the TARGET trial. *Journal of the American College of Cardiology* 2001;37:9A.
 91. Yen MH, Bhatt DL, Chew DP, Newby LK, White JA, **Moliterno DJ**, Topol EJ. Admission white blood cell count strongly and independently predicts mortality in acute coronary syndromes: the PARAGON A Study. *Circulation* 2001;104:II-389.
 92. Alexander KP, Bhapkar MV, White HD, Hochman JS, Pfisterer ME, **Moliterno DJ**, Topol EJ, Califf RM, Peterson ED, Van de Werf F, Armstrong PW, Newby LK. Paradoxical use of angiography with advancing age: insights from an international ACS trial population. *Journal of the American College of Cardiology* 2002;39:152A.
 93. Berger PB, **Moliterno DJ**, White J, Best P, Chan AW, Kristensen SD, Holmes, Jr. DR, DiBattiste PM, Herrmann HC, Topol EJ for the TARGET Investigators. Renal insufficiency and its relation to ischemic and bleeding outcomes with tirofiban versus abciximab in the TARGET trial. *Journal of the American College of Cardiology* 2002;39:27A.
 94. Bertrand M, **Moliterno DJ**, Neumann FJ, Ardissino D, DiBattiste P, Topol EJ. Geographic differences in clinical characteristics and long-term clinical outcome in the TARGET Study. *European Heart Journal* 2002;23:103.
 95. Chan AW, Bhatt DL, Chew DP, Quinn MJ, **Moliterno DJ**, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. *Journal of the American College of Cardiology* 2002;39:16A.
-

-
96. Chan AW, **Moliterno DJ**, Berger PB, Bhatt DL, DiBattiste PM, Yakubov S, Wolski K, Topol EJ. Clopidogrel pre-treatment prior to percutaneous coronary stenting reduces major adverse cardiac events, including mortality. Results from TARGET sub-analysis. *Circulation* 2002;106;II-517.
 97. Cho L, Chew DP, Roffi M, **Moliterno DJ**, Reginelli J, Aronow H, Chan AW, Quinn M, Gum P, Lincoff AM. Bivalirudin appears to be safe and efficacious with GP IIb/IIIa inhibitors. *Circulation* 2002;106;II-494.
 98. Cho L, Reginelli J, Lincoff AM, Roffi M, Kaldus T, Kottke-Marchant K, Mize PD, **Moliterno DJ**. A new, rapid ecarin clotting time assay but not activated clotting time strongly correlates with bivalirudin concentration: a percutaneous coronary intervention study. *Journal of the American College of Cardiology* 2002;39:17A.
 99. **Moliterno DJ**, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Jia G, Chew DP, Cohen DM, Stone GW, Demopoulos L, Topol EJ for the TARGET Investigators. Prolongation of activated clotting time (ACT) with tirofiban versus abciximab and its association to outcome. Results from TARGET. *Journal of the American College of Cardiology* 2002;39:74A.
 100. Mukherjee D, Gurm H, Tang W, Roffi M, Wolski K, **Moliterno DJ**, Guetta V, Ardissino D, Bode C, Steg G, Lincoff AM, Topol EJ. Improved outcome of acute ST-segment-elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. *Journal of the American College of Cardiology* 2002;39:293A.
 101. Roffi M, Cho L, Bhatt DL, White JA, **Moliterno DJ**, Harrington RA, Topol EJ. Dramatic increase in 30-day mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. *Journal of the American College of Cardiology* 2002;39:313A.
 102. Steinhubl S, Saucedo J, Sane D, Berger P, **Moliterno DJ**, Tcheng J, Kereiakes D. Point-of-care measurement of platelet function before angioplasty strongly predicts early MACE and late TVR. *European Heart Journal* 2002;23:222.
 103. Steinhubl SR, Saucedo JF, Sane DC, Berger PB, **Moliterno DJ**, Tcheng JE, Kereiakes DJ. Point-of-care platelet function prior to PCI, as measured by a point-of-care assay, strongly predicts future target vessel revascularization. *Journal of the American College of Cardiology* 2002;39:72A.
 104. Stone GW, **Moliterno DJ**, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Cohen M, Piedmonte M, DiBattiste PM. *Journal of the American College of Cardiology* 2002;39:22A.
 105. Casserly IP, Casserly LF, Aronow HD, Reginelli J, Sachar R, Exaire C, Dauteman KW, Tuzcu EM, **Moliterno DJ**, Bhatt DL, Ellis SG. Diabetes is an independent predictor of increased mortality following contemporary percutaneous coronary intervention for proximal left anterior descending artery disease. *Journal of the American College of Cardiology* 2003;41:28A.
 106. Casserly IP, Kereiakes DJ, Gray WA, Gibson P, Lauer MA, Reginelli JP, **Moliterno DJ**. New, rapid ecarin clotting time assay strongly correlates with bivalirudin concentration among PCI patients. *European Heart Journal* 2003;24(Abst Suppl):195.
 107. Chen MS, Bhatt DL, Chew DP, **Moliterno DJ**, Ellis SG. The irony of low utilization but comparable outcomes among African American and White patients after percutaneous coronary intervention. *Circulation* 2003;108:IV-717.
-

108. Chiu JH, Bhatt DL, **Moliterno DJ**, Ellis SG. Peripheral arterial disease independently predicts higher mortality following percutaneous coronary intervention. *Circulation* 2003;108:IV-358.
109. Exaire JE, Dauerman HL, **Moliterno DJ**, Blankenship JC, Raymond RE, Powers ER, Cohen EA, Topol EJ. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices: results from TARGET. *Journal of the American College of Cardiology* 2003;41:18A.
110. Exaire JE, Tchong JE, Kereiakes DJ, Kleiman NS, Applegate RJ, **Moliterno DJ**. Closure devices and vascular complications among PCI patients receiving enoxaparin, GP IIb/IIIa inhibitors and clopidogrel: insight from ELECT. *Circulation* 2003;108:IV-356.
111. Kaldus T, Cho L, Davis R, Swan H, Lincoff AM, **Moliterno DJ**, Kottke-Marchant K. Issues in monitoring direct thrombin inhibitors: comparison of a new, rapid ecarin clotting time (ECT) test to activated clotting time (ACT) and anti-IIa assays. *Journal of Thrombosis and Haemostasis* 2003;1Suppl:P1910.
112. McCarthy JJ, Parker A, **Moliterno DJ**, Rogers W, Newby LK, Cannata R, Glatt K, Topol EJ for the GENEQUEST Investigators. High-throughput genotyping for identification of genes underlying coronary artery disease: cumulative perspective from 222 polymorphisms 111 candidate genes. *Circulation* 2003;108:IV-49.
113. Merlini PA, Niguarda O, Rossi ML, Menozzi A, di Parma OC, **Moliterno DJ**, Topol EJ, Ardissino D. Thrombocytopenia with abciximab versus tirofiban and its association with clinical outcome. *Circulation* 2003;108:IV-417.
114. **Moliterno DJ**, Hermiller JB, Kottke-Marchant K, Kereiakes DJ, Kleiman NS, Tchong JE. Rapid point-of-care assessment of enoxaparin activity during percutaneous coronary interventions: the ELECT Study. *Journal of Thrombosis and Haemostasis* 2003;1Suppl:P0525a.
115. Rebeiz AG, Green CL, Johanson P, Giugliano RP, Harrington RA, **Moliterno DJ**, Roe MT, Newby KL, Crater SW, Langer A, Krucoff MW. ST-segment recovery with combination versus stand-alone thrombolytic therapy in ST-segment-elevation myocardial infarction is time-dependent: pooled data from PARADIGM, IMPACT-AMI, GUSTO-V, INTEGRITI. *Circulation* 2003;108:IV-361.
116. Roffi M, **Moliterno DJ**, Lauer MS, Reginelli J, Jia G, Topol EJ. Platelet glycoprotein IIb/IIIa antagonists are beneficial in patients with acute coronary syndromes who undergo in-hospital coronary artery bypass surgery. *Journal of the American College of Cardiology* 2003;41:351A.
117. Sadeghi HM, Grines CL, **Moliterno DJ**, White J, Herrmann H, Powers ER, Cohen DJ, Bertrand ME, Neumann FJ, DiBattiste PM, Stone GW, Topol EJ. Timing and risk factors for enzymatic myocardial infarctions in patients undergoing percutaneous intervention: insights from TARGET. *Journal of the American College of Cardiology* 2003;41:26A.
118. Schoenhagen P, Tuzcu EM, Stillman AE, **Moliterno DJ**, Halliburton SS, Kuzmiak SA, Kasper JM, Magyar WA, Lieber ML, Nissen SE, White RD. Non-invasive assessment of atherosclerotic plaque morphology and remodeling response in mildly stenotic coronary segments: direct comparison of multi-slice computed tomography and intravascular ultrasound. *Circulation* 2003;108:IV-528.

-
119. Triscott M, Mahan D, De Anglis A, Leumas J, McCallum S, **Moliterno DJ**. The rapidpoint ENOX point-of-care test has strong correlation with anti-Xa levels for detecting the anticoagulant effects of enoxaparin. *Journal of Thrombosis and Haemostasis* 2003;1Suppl:P1861.
 120. Vivekananthan DP, Bhatt DL, Chew DP, Chan AW, **Moliterno DJ**, Ellis SG, Topol EJ. Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive protein. *Journal of the American College of Cardiology* 2003;41:24A.
 121. Brener S, **Moliterno DJ**, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Are activated clotting time measurements still needed during percutaneous coronary interventions? Analysis of 4 randomized clinical trials. *European Heart Journal* 2004;25(Abst. Suppl):308.
 122. Crespo EM, Becker RC, Berger PB, Granger CB, Kleinman NS, **Moliterno DJ**, Moll S, Rice L, Abrams CS, Rogers J, Steinhubl S, Tapson VF, Anstrom KJ, Ohman EM. Incidence and evaluation of heparin-induced thrombocytopenia (HIT) among patients treated with prolonged heparin and among thrombocytopenia patients in the cardiac care unit: preliminary results of the CATCH Registry. *Journal of the American College of Cardiology* 2004;43:501A.
 123. Crespo EM, Granger CB, Becker RC, Berger PB, Kleiman NS, Moll S, **Moliterno DJ**, Rice L, Abrams CS, Rodgers JE, Steinhubl SS, Tapson VF, Honeycutt EF, Anstrom KJ, Ohman EM. Incidence, evaluation and outcomes of heparin-induced thrombocytopenia (HIT) among cardiac care unit patients: insights from the CATCH Registry. *Circulation* 2004;110:III-370.
 124. Martin JL, Shapiro TA, Martin SS, Herrmann HC, Jia G, DiBattiste PM, **Moliterno DJ**, Main Line Health, Mawr, B, PA. Relationship of obesity to target vessel revascularization and other outcomes following coronary stenting: observations from the TARGET trial. *Journal of the American College of Cardiology* 2004;43:81A.
 125. Moll S, Abrams CS, Rice L, Becker RC, Anstrom KJ, Honeycutt EF, Crespo EM, Granger C, **Moliterno DJ**, Rodgers JE, Steinhubl SR, Tapson VF, Ohman M. Thrombocytopenia is more common and nadir occurs earlier with unfractionated heparin than with LMWH: results from the prospective CATCH Registry. *American Society of Hematology Annual Meeting* 2004.
 126. Oliveira G, Anstrom K, **Moliterno DJ**, Abrams C, Becker R, Steinhubl S, Granger C, Ohman EM on behalf of the CATCH Registry Investigators. Heparin-induced thrombocytopenia (HIT) is common and associated with poor outcomes, yet uncommonly evaluated and detected: preliminary results of the multi-center CATCH Registry. *European Heart Journal* 2004;25(Abst. Suppl):93.
 127. Oliveira GBF, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, Granger CB, Kleiman NS, **Moliterno DJ**, Moll S, Rice L, Rodgers JE, Steinhubl SS, Tapson VF, Ohman EM. Predictors of thrombocytopenia, HIT serologic screening, and mortality in patients receiving prolonged (>96 h) heparin therapy: findings from the CATCH Registry. *Circulation* 2004;110:III-559.
 128. Rodgers JE, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, Granger CB, Kleiman NS, **Moliterno DJ**, Moll S, Rice L, Steinhubl SS, Tapson VF, Ohman EM. Withholding direct thrombin inhibitor treatment while awaiting laboratory confirmation of heparin-induced thrombocytopenia is associated with an increased rate of thromboembolic complications: results of the CATCH Registry. *Circulation* 2004;110:III-371.
-

-
129. Zidar FJ, **Moliterno DJ**, Bhatt DL, Kottke-Marchant K, Goormastic M, Plow EF, Topol EJ. High-dose clopidogrel loading rapidly reduces both platelet inflammatory marker expression and aggregation. *Journal of the American College of Cardiology* 2004;43:64A.
 130. **Moliterno DJ**, Moll S, Ohman EM, Granger CB, on behalf of CATCH Registry Investigators. Intravenous unfractionated heparin, patient profile and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH Registry. *European Heart Journal* 2005;26(Abst. Suppl.):725.
 131. Ohman EM, Abrams CS, Honeycutt EF, Becker RC, Crespo EM, Anstrom KJ, **Moliterno DJ**, Rice L, Rodgers JE, Steinhubl SR, Granger CB. High mortality after discharge among patients with high risk for developing heparin-induced thrombocytopenia or thrombosis: 6-month follow-up results of the CATCH Registry. *Journal of the American College of Cardiology* 2005;45(Suppl. A):411A.
 132. Oliveira GBF, Anstrom KJ, Honeycutt EF, Becker RC, **Moliterno DJ**, Moll S, Ohman EM, Granger CB. Intravenous unfractionated heparin, patient clinical profile and the magnitude of reduction in platelet count are associated with detection of heparin-induced thrombocytopenia (HIT) antibodies and occurrence of thromboembolic events: results from the CATCH Registry. *European Society of Cardiology Scientific Sessions* 2005.
 133. Saw J, Topol EJ, **Moliterno DJ**, Brener SJ, Steinhubl SR, Lincoff AM, Hu TF, Bhatt DL. The pivotal influence of peripheral vascular disease on coronary intervention outcomes: a pooled analysis of mortality outcomes in 8 large randomized percutaneous coronary intervention trials. *Journal of the American College of Cardiology* 2005;45(Suppl A):440A.
 134. Westerhout CM, Mahaffee KW, Theroux P, White H, Armstrong PW, **Moliterno DJ**, Simoons ML, Boersma E. Incidence and predictors of stroke in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): insights from 6 major intravenous glycoprotein IIb/IIIa inhibitors trials. *ESC* 2005.
 135. Oliveria GB, Anstrom KJ, Honeycutt EF, Abrams CS, Becker RC, Berger PB, **Moliterno DJ**, Moll S, Rice L, Kleiman N, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB. Prolonged heparin exposure, development of thrombocytopenia, use of GP IIb/IIIa inhibitors, and history of renal dysfunction predict moderate or severe bleeding: a report from the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. *Journal of the American College of Cardiology* 2006;47(Suppl. A):251A.
 136. Latif F, Saucedo JF, Kleiman NS, Cutlip D, Marulka S, **Moliterno DJ**, Nassif D, Lopez JJ, Cohen DJ. Clinical outcomes of patients with chronic kidney disease undergoing percutaneous coronary intervention in the drug-eluting stent era. *30th Annual Scientific Sessions* 2006.
 137. Mardikar HM, Hiremath MS, **Moliterno DJ**, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande N, Khan A, Joseph J, Mukherjee D. Optimal platelet inhibition in patients undergoing PCI: data from the multi-center registry of high-risk percutaneous coronary intervention and adequate platelet inhibition (MC PCI) Study. *Journal of the American College of Cardiology* 2007;49(Suppl B):34B.
 138. Armstrong PW, Fu Y, Brener SJ, Todaro TG, **Moliterno DJ**, Holmes DR, Adams PX, Westerhout CM, Wagner GS, Granger CB, APEX AMI Investigators. Myocardial perfusion in ST-elevation myocardial infarction patients following primary percutaneous coronary intervention: insights from the Electrocardiography/Angiography Substudy of APEX AMI. *Journal of the American College of Cardiology* 2007;49(Suppl A):249A.
-

139. Jolicœur ME, Ohman ME, Honeycutt EF, Mazon FJN, Beckerd RC, Crespo EM, Oliveira GBF, **Moliterno DJ**, Anstrom KJ, Granger CB, Duke Clinical Research Institute. Bleeding is common among patients treated with heparin experiencing thrombocytopenia and confers a high mortality risk: report from the CATCH Registry. *Journal of the American College of Cardiology* 2007;49(Suppl A):340A.
140. Theroux P, Armstrong PW, **Moliterno DJ**, Neumann FJ, Stebbins AL, Mahaffey KW, Hochman JS, Hamm CW, Granger CB, APEX AMI Investigators. Do selected markers of inflammatory response during the acute phase of STEMI relate to outcome? *Journal of the American College of Cardiology* 2008;51(Suppl A):A185.
141. Shah AM, Kuvlieva L, Ziada K, Hamdalla H, Booth DC, Gurley JC, **Moliterno DJ**, Mukherjee D. Adherence to evidence-based therapy guidelines in patients undergoing peripheral arterial interventions. *Journal American College of Cardiology* 2009;53(Suppl A):A451.
142. Whitbeck M, Charnigo R, Fornwalt B, Morales G, Shah J, Zegarra MM, Bailey A, Anaya P, Macaulay T, Campbell C, Gurly J, Ziada K, Rong B, Di Biase L, Natal A, Smyth S, **Moliterno DJ**, Elayi CS. Increased Morbidity and Mortality among Atrial Fibrillation Patients with Prolonged QRS: Results from the AFFIRM study. *Journal American College of Cardiology* 2012;59(Suppl A):A150.
143. Leonardi S, Tricoci P, White H, Armstrong P, Huang Z, Wallentin L, Aylward P, **Moliterno DJ**, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick T, Harrington R, Mahaffey K. Reduction of Myocardial Infarction with Vorapaxar: Results from the TRACER Trial. *Journal American College of Cardiology* 2012;59(Suppl A):A123.
144. Baber, U, Colombo A, Weisz G, Chieffo A, Gibson CM, Alu M, Barathi P, Sergie Z, Cohen D, **Moliterno DJ**, Witzenbichler B, Krucoff M, Steg P, Mehran R. Association of Stent Thrombosis and Patterns of Non-Adherence to Anti-platelet Regimens in Stented Patients: Six Month Results of the PARIS Registry. *Journal American College of Cardiology* 2012;59(Suppl A):A65.
145. Cornel JH, Tricoci P, Horton J, **Moliterno DJ**, Wallentin L, Armstrong P, Aylward P, Huang Z, Lokhnygina Y, Chen E, Leonardi S, Van de Werf F, White H, Held C, Strony J, Mahaffey K, Harrington R. Effects of Glycoprotein IIb/IIIa Inhibitors in Combination with Vorapaxar, A Platelet Thrombin-Receptor Antagonist, Among Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From The TRACER Trial. *Journal American College of Cardiology* 2013;61(Suppl).
146. Hess PL, Tricoci P, Horton J, Lokhnygina Y, Al-Khatib SM, Piccini J, Harrington R, Armstrong P, Aylward P, **Moliterno DJ**, Van de Werf F, Wallentin L, White H, Held C, Mahaffey K. Incidence and Predictors of Sudden Cardiac Death After Hospitalization for Non-ST-Segment Elevation Myocardial Infarction: An Analysis from the TRACER Trial. *Journal American College of Cardiology* 2013;61(Suppl).
147. Gukathasan N, Weisz G, Witzenbichler B, Kini A, Henry T, Sartori S, Baber U, Cohen D, Chieffo A, Hermiller J, Stuckey T, Shawl F, **Moliterno DJ**, Antoniucci D, Berger P, Waksman R, Colombo A, Mehran R. Frequency and Impact of Single Versus Dual Antiplatelet Cessation on Adverse Cardiac Events: Results from the PARIS Registry. *Journal American College of Cardiology* 2013;61(Suppl).

148. Kherada N, Sartori S, Vadde R, Bharathi P, Cohen D, **Moliterno DJ**, Steg P, Henry T, Weisz G, Witzenbichler B, Colombo A, Mehran R. Predictors of Dual Antiplatelet Therapy Non-Adherence After PCI: One-Year Insights from the PARIS Registry. *Journal American College of Cardiology* 2013;61(Suppl).
149. Jones S, Tricoci P, Huang Z, **Moliterno DJ**, Harrington RA, Sinnaeve P, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW. Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER. *Circulation* 2013;128:A17939.
150. Dery JP, Mahaffey K, Tricoci P, White H, Podder M, **Moliterno DJ**, Harrington R, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward P, Armstrong PW, Rao S. Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar. *Circulation* 2013;128:A10742.

**Abstract listing abridged at first 150.*

Publications – Journal Articles

1. Brogan WC, Lange RA, Kim AS, **Moliterno DJ**, Hillis LD. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. *Journal of the American College of Cardiology* 1991;18:581-586. PMID: 1906905
2. Boehrer JD, **Moliterno DJ**, Willard JE, Snyder RW, Horton RP, Glamann DB, Lange RA, Hillis LD. Hemodynamic effects of intranasal cocaine in humans. *Journal of the American College of Cardiology* 1992;20:90-93. PMID: 1607544
3. **Moliterno DJ**, DeBold CR, Robertson RM. Coronary vasospasm—relation to the hyperthyroid state. *American Journal of the Medical Sciences* 1992;304:38-42. PMID: 1642252
4. **Moliterno DJ**, Lange RA, Willard JE, Boehrer JD, Hillis LD. Does restoration of antegrade flow in the infarct-related coronary artery days to weeks after myocardial infarction improve long-term survival? *Coronary Artery Disease* 1992;3:299-304. PMID: n/a
5. Boehrer JD, **Moliterno DJ**, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced vasoconstriction in humans. *American Journal of Medicine* 1993;94:608-610. PMID: 8506886
6. **Moliterno DJ**, Jessen ME, Schueler KA, Cohen J. Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass. *Atherosclerosis* 1993;104:223-225. PMID: 8141847
7. **Moliterno DJ**, Lange RA, Meidell RS, Willard JE, Leffert CC, Boerwinkle EA, Gerard RD, Hobbs HH, Hillis LD. Relation of lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. *Circulation* 1993;88:935-940. PMID: 8353920
8. **Moliterno DJ**, Lange RA, Willard JE, Boehrer JD, Hillis LD. Surgical restoration of antegrade flow in the occluded infarct artery improves long-term survival in patients with multivessel coronary artery disease. *Coronary Artery Disease* 1993;4:995-999. PMID: 8173717
9. Taylor GA, **Moliterno DJ**, Hillis LD. Peripartum myocardial infarction. *American Heart Journal* 1993;126:1462-1463. PMID: 8249804
10. **Moliterno DJ**, Lange RA, Gerard RD, Willard JE, Lackner C, Hillis LD. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. *American Journal of Medicine* 1994;96:492-496. PMID: 8017445
11. **Moliterno DJ**, Willard JE, Lange RA, Negus BH, Boehrer JD, Glamann DB, Landau C, Rossen JD, Winniford MD, Hillis LD. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. *New England Journal of Medicine* 1994;330:454-459. PMID: 8289850
12. **Moliterno DJ**, Califf RM, Aguirre F, Anderson K, Sigmon KN, Weisman HF, Topol EJ and EPIC Study Investigators. Effect of platelet glycoprotein IIb/IIIa integrin blockade during percutaneous transluminal coronary angioplasty and directional coronary atherectomy (the EPIC trial). *American Journal of Cardiology* 1995;75:559-562. PMID: 7887377
13. **Moliterno DJ**, Harrington RA, Califf RM, Rapold HJ, Topol EJ. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: rationale and design for the PARADIGM Study. *Journal of Thrombosis and Thrombolysis* 1995;2:165-169. PMID: 10608020

14. **Moliterno DJ**, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle EA, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1995;15:850-855. PMID: 7600116
15. Nissen SE, De Franco AC, Tuzcu EM, **Moliterno DJ**. Coronary intravascular ultrasound: diagnostic and interventional applications. *Coronary Artery Disease* 1995;6:355-367. PMID: 7655722
16. Gottsauner-Wolf M, **Moliterno DJ**, Lincoff AM, Topol EJ. Restenosis—an open file. *Clinical Cardiology* 1996;19:347-356. PMID: 8723592
17. Mak KH, Belli G, Ellis SG, **Moliterno DJ**. Subacute stent thrombosis: evolving issues and current concepts. *Journal of the American College of Cardiology* 1996;27:494-503. PMID: 8557927
18. Migrino RQ, **Moliterno DJ**, Topol EJ. Preinfarction angina does not influence thrombolytic outcome (letter). *New England Journal of Medicine* 1996;335:59-61. PMID: 8637552
19. **Moliterno DJ**, Topol EJ. Another step toward resolving the contrast controversy. *Journal of the American College of Cardiology* 1996;27:1387-1389. PMID: 8626948
20. Mak KH, **Moliterno DJ**, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *Journal of the American College of Cardiology* 1997;30:171-179. PMID: 9207639
21. **Moliterno DJ**, Topol, EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. *Thrombosis and Hemostasis* 1997;78:214-219. PMID: 9198156
22. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, **Moliterno DJ**, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. *Circulation* 1997;96:76-81. PMID: 9236420
23. Steinhubl SR, **Moliterno DJ**. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina. *Heart and Vessels* 1997;12:148-155. PMID: 9476567
24. Wallace RC, Furlan AJ, **Moliterno DJ**, Stevens G, Perl JII. Basilar artery re-thrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. *American Journal of Neurologic Radiology* 1997;18:1257-1260. PMID: 9282851
25. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, **Moliterno DJ**, Effron MB, Topol EJ on behalf of RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. *Circulation* 1998;98:734-741. PMID: 9727542

-
26. Every NR, Cannon CP, Granger CB, **Moliterno DJ**, Aguirre FV, Talley JD, Booth J, Sapp S, Ferguson JJ for the GUARANTEE Investigators. Influence of insurance type on the use of procedures, medications, and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. *Journal of the American College of Cardiology* 1998;32:387-392. PMID: 9708465
 27. Kong DF, Califf RM, Miller DP, **Moliterno DJ**, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. *Circulation* 1998;98:2829-2835. PMID: 9860783
 28. **Moliterno DJ** for the PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. *Circulation* 1998;97:2386-2395. PMID: 9641689
 29. Roe MT, **Moliterno DJ**. Use of glycoprotein IIb/IIIa inhibitors to prevent ischemic complications during percutaneous revascularization: review of the EPILOG trial. *Cleveland Clinic Journal of Medicine* 1998;65:267-272. PMID: 9599910
 30. Roe MT, Tayara W, **Moliterno DJ**. Contemporary myocardial revascularization. *Cardiology Special Edition* 1998;4:25-30. PMID: N/A
 31. Steinhubl SR, Lauer MS, Mukherjee DP, **Moliterno DJ**, Lincoff AM, Ellis SG, Topol, EJ. The duration and pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. *Journal of the American College of Cardiology* 1998;32:1366-1370. PMID: 9809949
 32. Tan WA, **Moliterno DJ**. Editorial: TIMI flow and surrogate endpoints: What you see is not always what you get. *American Heart Journal*, 1998;136:570-573. PMID: 9778057
 33. Asher CA, Topol EJ, **Moliterno DJ**. Insights into the pathophysiology of atherosclerosis and prognosis of black and white Americans with acute coronary syndromes. *American Heart Journal*, 1999;138:1073-1081. PMID: 10577437
 34. Lincoff AM, Califf RM, **Moliterno DJ**, Tcheng JE, Ellis SG, Ducas J, Kramer JH, Talley JD, Caramori PO, Kleiman NS, Cohen EA, Burton JR, Kelly TA, Booth JE, Sapp SK, Ivanc TB, Cabot CF, Topol EJ for the EPISTENT Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. *New England Journal of Medicine* 1999;341:319-327. PMID: 10423466
 35. Mak KH, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. *Current Cardiology Reports: Antithrombotics in the Management of Patients with Acute Coronary Syndromes*. *Current Cardiology Reports* 1999;1:199-205. PMID: 10980842
 36. **Moliterno DJ**. Lamifiban: a personal commentary on its use. *Drugs* 1999;57:222-223.
 37. Patel V, **Moliterno DJ**. Invasive versus conservative management of non-Q-wave myocardial infarction. *The Cleveland Clinic Journal of Medicine* 1999;66:100-104. PMID: 9988955
 38. Patel VB, **Moliterno DJ**. Editorial: Bedside activated partial thromboplastin monitoring: just a matter of time? *American Heart Journal* 1999;137:8-11. PMID: 9878931
-

39. Patel VB, **Moliterno DJ**. Optimal use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: which patients should be treated? *Cardiology Special Edition* 1999;5:41-48.
40. Roe MT, **Moliterno DJ**. Emerging treatment of acute coronary syndromes with platelet IIb/IIIa inhibitors. *Journal of Thrombosis and Thrombolysis* 1999;7:247-257. PMID: 10373718
41. Roe MT, **Moliterno DJ**. Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. *Journal of Emergency Medicine* 1999;17:581-588. PMID: 10338260
42. Scirica BM, **Moliterno DJ**, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp S, Booth JE, Ferguson JJ, Cannon CP for the GUARANTEE Investigators. Racial differences in the management of unstable angina: results from the multi-center GUARANTEE Registry. *American Heart Journal* 1999;138:1065-1072. PMID: 10577436
43. Scirica BM, **Moliterno DJ**, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Sapp S, Booth JE, Ferguson JJ, Cannon CP, and the GUARANTEE Investigators. Differences between men and women in the management of unstable angina pectoris: results from the multi-center GUARANTEE Registry. *American Journal of Cardiology* 1999;84:1145-1150. PMID: 10569321
44. Steinhubl SR, Kottke-Marchant K, **Moliterno DJ**, Rosenthal ML, Godfrey NK, Collier BS, Topol EJ, Lincoff AM. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. *Circulation* 1999;100:1977-1982. PMID: 10556224
45. Tan WS, **Moliterno DJ**. The role of aspirin, ticlopidine, and clopidogrel in acute coronary syndromes. *The Cleveland Clinic Journal* 1999;66:615-628. PMID: 10598366
46. Bhatt DL, **Moliterno DJ**. Enoxaparin and glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. *Journal of Invasive Cardiology* 2000;2:10.
47. Brener SB, Ellis SG, Sapp SK, Betriu A, Granger CB, Burchenal JE, **Moliterno DJ**, Califf RM, Topol EJ for the GUSTO IIb and RAPPORT Investigators. Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials. *American Heart Journal* 2000;139:476-481. PMID: 10689262
48. Casserly IP, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa receptor antagonists. *Expert Opinion in Pharmacotherapy* 2000;1:419-433. PMID: 11249527
49. Chew D, **Moliterno DJ**. A critical appraisal of platelet glycoprotein IIb/IIIa inhibitors. *Journal of the American College of Cardiology* 2000;36:2028-2035. PMID: 11127436
50. Chew D, **Moliterno DJ**. Facilitated percutaneous coronary intervention for acute myocardial infarction. *Acute Coronary Syndromes* 2000;3:34-41.
51. Cura F, L'Allier PL, Tan WA, Wolsky KE, **Moliterno DJ**, Brener SJ, Lincoff AM, Ellis SG, Topol EJ. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. *Circulation* 2000;102:28-34. PMID: 10880411

52. Herrmann HC, **Moliterno DJ**, Ohman EM Stebbins A, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-IV Pilot) trial. *Journal of the American College of Cardiology* 2000;36:1489-1496. PMID: 11079647
 53. Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B, Zidar J, Casale P, Christy G, **Moliterno DJ**, Lengerich R, Broderick T, Shimshak T, Cohen M. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." *Journal of Invasive Cardiology* 2000;12:1A-5A. PMID: 10731289
 54. Mak KH, Effron MB, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. *Drugs & Aging* 2000;16:179-187. PMID: 10803858
 55. McGuire DK, Emanuelsson H, Granger CB, Ohman EM, **Moliterno DJ**, White HD, Ardissino D, Box JW, Califf RM, Topol EJ for the GUSTO-IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. *European Heart Journal* 2000;21:1750-1758. PMID: 11052839
 56. **Moliterno DJ**, Mukherjee D. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. *American Heart Journal* 2000;140:S136-142. PMID: 11100007
 57. **Moliterno DJ**, Topol EJ. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET Study. The TARGET International Steering Committee. *American Heart Journal* 2000;140:722-726. PMID: 11054616
 58. **Moliterno DJ**. Combination therapy: management of acute myocardial infarction in the new millennium. *Journal of Emergency Medicine* 2000;19:S33-S38. PMID: 11050382
 59. **Moliterno DJ** for the PARAGON B International Steering Committee. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design for the PARAGON-B Study. *American Heart Journal* 2000;139:563-566. PMID: 10740135
 60. Mukherjee D, **Moliterno DJ**. Achieving tissue-level perfusion in the setting of acute myocardial infarction. *American Journal of Cardiology* 2000;85:39C-46C. PMID: 10793179
 61. Mukherjee D, **Moliterno DJ**. Applications of antiplatelet monitoring in the catheterization laboratory. *Journal of Thrombosis and Thrombolysis* 2000;9:293-301. PMID: 10728030
 62. Mukherjee D, **Moliterno DJ**. Prompt use of reteplase (RetevasTM) for acute myocardial infarction: facilitating percutaneous intervention and early hospital discharge. *The Journal of Invasive Cardiology* 2000;2:2. PMID: N/A
 63. Mukherjee D, Reginelli JP, **Moliterno DJ**, Schneider JP, Raymond R, Whitlow PL, Franco I, Topol EJ, Ellis SG. Unexpected mortality reduction with abciximab for in-stent restenosis. *The Journal of Invasive Cardiology* 2000;12:540-544. PMID: 11060563
 64. Mukherjee D, **Moliterno DJ**. Monitoring antiplatelet therapy: what is the best method? *Clinical Pharmacokinetics* 2000;39:445-458. PMID: 11192476
-

-
65. Patel VB, **Moliterno DJ**. Glycoprotein IIb/IIIa antagonists and fibrinolytic agents: new therapeutic regimen for acute myocardial infarction. *Journal of Invasive Cardiology* 2000;12 (Suppl);8B-15B. PMID: 10731294
 66. Patel VB, **Moliterno DJ**. Glycoprotein IIb/IIIa receptor antagonists in percutaneous coronary intervention. *Cardiology Special Edition* 2000;6:63-99.
 67. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A, Stebbins A, **Moliterno DJ**, Califf RM on behalf of the GUSTO-III Investigators. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the GUSTO III Trial. *Circulation* 2000;102:1761-1765. PMID: 11023929
 68. Casterella PJ, Kereiakes DJ, Steinhubl SR, Raymond RE, Kottke-Marchant K, Patel K, Mueller M, Rosenthal M, **Moliterno DJ**, Teirstein PS. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. *Catheter Cardiovascular Interventions* 2001;54:497-504. PMID: 11747189
 69. Chan AW, **Moliterno DJ**. Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. *Current Opinion in Cardiology* 2001;16:375-383. PMID: 11704709
 70. Chan AW, **Moliterno DJ**. In-stent restenosis: update on intracoronary radiotherapy. *Cleveland Clinic Journal of Medicine* 2001;68;796-803. PMID: 11563483
 71. Chew DP, **Moliterno DJ**. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. *Cleveland Clinic Journal of Medicine* 2001;68:1017-1023. PMID: 11765119
 72. Chew DP, Bhatt DL, Lincoff AM, **Moliterno DJ**, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. *Circulation* 2001;103:961-966. PMID: 11181470
 73. Cho L, Bhatt DL, Wolski K, Lincoff AM, Topol EJ, **Moliterno DJ**. Effect of smoking status and abciximab use on the outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT. *American Heart Journal* 2001;141:599-602. PMID: 11275926
 74. Ellis SG, Brener SJ, Lincoff AM, **Moliterno DJ**, Whitlow PL, Schneider JP, Topol EJ. Beta-blockers before percutaneous coronary intervention do not attenuate post-procedural creatine kinase isoenzyme rise. *Circulation* 2001;104:2685-2688. PMID: 11723019
 75. Estess JM, **Moliterno DJ**. Thrombolytic therapy for acute myocardial infarction. *Catheterization and Cardiovascular Intervention* 2001;53:489-498. PMID: 11514999
 76. Kaul P, Fu Y, Chang W-C, Harrington RA, Wagner GS, Goodman SG, Granger CB, **Moliterno DJ**, Van de Werf F, Califf RM, Topol EJ, Armstrong PW for the PARAGON-A and GUSTO-IIb Investigators. Prognostic value of ST-segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. *Journal of the American College of Cardiology* 2001;38:64-71. PMID: 11451297
 77. Mukherjee D, Chew DP, Robbins M, Yadav JS, Raymond RE, **Moliterno DJ**. Clinical application of procedural platelet monitoring during percutaneous intervention among patients at increased bleeding risk. *Journal of Thrombosis and Thrombolysis* 2001;11:151-154. PMID: 11406730
-

78. Newby LK, Ohman EM, Christenson RH, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Van de Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ for the PARAGON-B Investigators. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin T substudy. *Circulation* 2001;103:2891-2896. PMID: 11413076
79. Quinn MJ, **Moliterno DJ**. Editorial: Troponins in acute coronary syndromes: more TACTICS for an early invasive strategy. *Journal of the American Medical Association* 2001;286:2461-2462. PMID: 11712942
80. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, **Moliterno DJ**, Califf RM, White HD, Kleiman NS, Thérout P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. *Circulation* 2001;104:2767-2771. PMID: 11733392
81. Sekaran NK, **Moliterno DJ**, Ferguson JJ, Every N, Anderson HV, Aguirre FV, French WJ, Sapp S, Booth JE, Granger CB, Cannon CP for the GUARANTEE Investigators. “Hot” unstable angina—is it worse than subacute unstable angina? Results from the GUARANTEE Registry. *Journal of Thrombosis and Thrombolysis* 2001;12:207-216. PMID: 11981103
82. Steinhubl SR, Talley JD, Kereiakes DJ, Braden GA, Tchong JE, Casterella PJ, **Moliterno DJ**, Navetta FI, Berger PB, Popma JJ, Dargas G, Gallo R, Sane DC, Jia G, Lincoff AM, Theroux P, Holmes DR Jr, Teirstein PS, Collier BS, Topol EJ. Point-of-care measured platelet inhibition correlates with a reduced risk of adverse cardiac event after percutaneous coronary intervention: results of the GOLD (Au-Assessing Ultegra) multi-center study. *Circulation* 2001;103:2572-2578. PMID: 11382726
83. Topol EJ, McCarthy J, Bolk S, **Moliterno DJ**, Rogers WJ, Newby LK, Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Plow EF, Stenina O, Lander ES, Daley GQ for the GeneQuest Investigators and Collaborators. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. *Circulation* 2001;104:2641-2644. PMID: 11723011
84. Topol EJ, **Moliterno DJ**, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann F-J, Stone GW, DiBattiste PM, Demopoulos L for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary revascularization. *New England Journal of Medicine* 2001;344:1888-1894. PMID: 11419425
85. Al-Khatib SM, Granger CC, Huang Y, Lee KL, Califf RM, Simoons ML, Armstrong PW, Van De Werf F, White HD, Simes JR, **Moliterno DJ**, Topol EJ, Harrington RA. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: Incidence, predictors, and outcomes. *Circulation* 2002;106:309-312. PMID: 12119245
86. Boersma E, Harrington RA, **Moliterno DJ**, White H, Theroux P, Van de Werf F, Pieper K, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. *The Lancet* 2002;359:189-198. PMID: 11812552

-
87. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, **Moliterno DJ**, Califf RM, Topol EJ, Ohman EM. Prognostic significance of elevated troponin I after percutaneous coronary intervention. *Journal of the American College of Cardiology* 2002;39:1738-1744. PMID: 12039485
 88. Chan AW, Bhatt DL, Chew DP, Quinn MJ, **Moliterno DJ**, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. *Circulation* 2002;105:691-696. PMID: 11839623
 89. Chan AW, Chew DP, Bhatt DL, **Moliterno DJ**, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. *American Journal of Cardiology* 2002;89:132-136. PMID: 11792330
 90. Chan AW, Quinn MJ, Bhatt DL, Chew DP, **Moliterno DJ**, Topol EJ, Ellis SG. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. *Journal of the American College of Cardiology* 2002;40:669-675. PMID: 12204496
 91. Chew DP, **Moliterno DJ**, Herrmann HC. Present and potential future paradigms for the treatment of ST-segment-elevation acute myocardial infarction. *Journal of Invasive Cardiology* 2002;14:3A-20A. PMID: 11847402
 92. Chew DP, **Moliterno DJ**. Managing unstable angina in high-risk patients. *Journal of Invasive Cardiology* 2002;31A:48A. PMID: 11847404
 93. Cho L, Smedira NG, White RD, **Moliterno DJ**. Giant saphenous vein graft aneurysm. *Cardiology in Review* 2002;10:247-248. PMID: 12144735
 94. Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, **Moliterno DJ**, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndrome (NSTE-ACE) and during percutaneous coronary intervention: an expert consensus. *American Heart Journal* 2002;144:615-624. PMID: 12360156
 95. **Moliterno DJ**, Topol EJ. The TARGET Trial. Hit or miss? *European Heart Journal* 2002;23:835-837. PMID: 12042001
 96. **Moliterno DJ**, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ for the TARGET Investigators. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET Study. *The Lancet* 2002;360:355-360. PMID: 12241774
 97. Mukherjee D, Gurm H, Tang W, Roffi M, Wolski K, **Moliterno DJ**, Guetta V, Ardissino D, Bode C, Steg G, Lincoff AM, Topol EJ. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. *American Journal of Cardiology* 2002;90:1198-1203. PMID: 12450598
 98. Mukherjee D, Mahaffey KW, **Moliterno DJ**, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer M, Mänttari M, White HD, Califf RC, Topol EJ. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from PARAGON B. *American Heart Journal* 2002;144:995-1002. PMID: 12486423
-

99. Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hoschman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, **Moliterno DJ** for the PARAGON A Investigators. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: Insights from PARAGON A. *Journal of Thrombosis and Thrombolysis* 2002;14:33-42. PMID: 12652148
100. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, **Moliterno DJ**, Verheugt FWA, Weaver WD, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. *Journal of the American Medical Association* 2002;287:3087-3095. PMID: 12069671
101. Quinn MJ, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *Minerva Cardioangiologica* 2002;50:547-553. PMID: 12384636
102. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, **Moliterno DJ**, Heeschen C, Hamm CW, Robbins MA, Kleinman NS, Theroux P, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. *European Heart Journal* 2002;23:1441-1448. PMID: 12208224
103. Roffi M, **Moliterno DJ**, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ for the TARGET Investigators. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: TARGET 1-year follow-up. *Circulation* 2002;105:2730-2736. PMID: 12057986
104. Scirica BM, Cannon CP, Gibson CM, Murphy SA, **Moliterno DJ**, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald E. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST-elevation myocardial infarction in the TIMI III and the GUARANTEE registries. *Critical Pathways in Cardiology* 2002;1:150-158. PMID: 18340298
105. Stone GW, **Moliterno DJ**, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. *Circulation* 2002;105:2347-2354. PMID: 12021219
106. Vivekananthan DP, **Moliterno DJ**. Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome. *Journal of Thrombosis and Thrombolysis* 2002;13:35-39. PMID: 11994558
107. Vivekananthan DP, Patel VB, **Moliterno DJ**. Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction. *Journal of Interventional Cardiology* 2002;15:131-139. PMID: 12063808
108. Wheeler GL, Braden GA, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller M, **Moliterno DJ**, Sane DC. Ultegra Rapid Platelet-Function Assay (RPFA): comparison to standard platelet-function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *American Heart Journal* 2002;143:602-611. PMID: 11923796

109. Brener SJ, Bhatt DL, **Moliterno DJ**, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. *American Journal of Cardiology* 2003;92:1468-1471. PMID: 14675590
110. Brener SJ, Midei MG, Nukta D, Kereiakes DJ, Rizik DG, Murphy D, Brennan D, **Moliterno DJ**. A randomized multi-center trial comparing a new, low-pressure versus a conventional coronary stent: primary results from the CONSERVE Trial. *Journal of Invasive Cardiology* 2003;15:128-132. PMID: 12612386
111. Casserly IP, Roffi M, **Moliterno DJ**. Platelet GP IIb/IIIa receptor inhibitors in diabetics undergoing PCI using stents. *Cardiology Review* 2003;20:9-13. PMID: n/a
112. Casserly IP, Topol EJ, Lange RA, Jia G, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, **Moliterno DJ**. Effect of abciximab versus tirofiban on activated clotting time during percutaneous coronary intervention and its relation to clinical outcomes – observations from the TARGET Trial. *American Journal of Cardiology* 2003;92:125-129. PMID: 12860211
113. Chan AW, **Moliterno DJ**, Berger PB, Stone GW, DiBattiste PM, Yakubov SJ, Sapp, S, Wolski K, Bhatt DL, Topol EJ for the TARGET Investigators. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including 1-year survival: results from do Tirofiban and ReoPro[®] Give Similar Efficacy Outcomes Trial (TARGET). *Journal of the American College of Cardiology* 2003;42:1188-1195. PMID: 14522478
114. Chan AW, **Moliterno DJ**. Optimization of glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: Insights from TARGET after 1 year. *Cardiovascular Reviews and Reports* 2003;24:506-513. PMID: n/a
115. Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, **Moliterno DJ**. Peripheral vascular disease and 1-year mortality following percutaneous coronary revascularization. *American Journal of Cardiology* 2003;92:582-583 PMID: 12943879
116. Cho L, Chew DP, **Moliterno DJ**, Roffi M, Ellis SG, Franco I, Bazjer C, Bhatt DL, Dorosti K, Simpfendorfer C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa inhibition. *American Journal of Cardiology* 2003;91:742-743. PMID: 12633814
117. Cho L, Kottke-Marchant K, Lincoff AM, Roffi M, Reginelli JP, Kaldus T, **Moliterno DJ**. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. *American Journal of Cardiology* 2003;91:1110-1113. PMID: 12714157
118. Khot UM, Jia G, **Moliterno DJ**, Lincoff AM, Khot MB, Harrington RA, Topol EJ. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): the enduring value of Killip classification. *Journal of the American Medical Association* 2003;290:2174-2181. PMID: 14570953
119. McCarthy JJ, Lehner T, **Moliterno DJ**, Newby LK, Rogers WJ, Topol EJ for the GeneQuest Investigators. Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease. *Journal of Medical Genetics* 2003;40:453-458 PMID: 12807968

120. McCarthy JJ, Meyer J, **Moliterno DJ**, Newby LK, Rogers WJ, Topol EJ. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. *Human Genetics* 2003;114:87-98. PMID: 14557872
121. **Moliterno DJ**, Chan AW. Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. *Journal of the American College of Cardiology* 2003;41:49-54. PMID: 12644341
122. **Moliterno DJ**, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA, Dippel EJ, Furman MI, Grines CL, Kleiman NS, Levine GN, Mann T, Nair RN, Stine RA, Yacubov SJ, Tcheng JE for the ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. *Journal of the American College of Cardiology* 2003;42:1132-1139. PMID: 13678943
123. **Moliterno DJ**, Penn MS. Angioplasty, inflammation, and antiplatelet agents. *American Heart Journal* 2003;145:563-566. PMID: 12679746
124. Mukherjee D, Hsu A, **Moliterno DJ**, Lincoff AM, Goormastic M, Topol EJ. Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients ≤ 40 years of age. *American Journal of Cardiology* 2003;92:1465-1467. PMID: 14675589
125. Quinn MJ, **Moliterno DJ**. Diabetes and percutaneous coronary intervention: the sweet smell of success? *American Heart Journal* 2003;145:203-205. PMID: 12595833
126. Roffi M, **Moliterno DJ**, Lauer MS, Reginelli J, Jia G, Topol EJ. Platelet glycoprotein IIb/IIIa antagonists are beneficial in patients with acute coronary syndromes who undergo in-hospital coronary artery bypass surgery. *Journal of the American College of Cardiology* 2003;41:351-352. PMID: n/a
127. Ross MJ, Herrmann HC, **Moliterno DJ**, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Frey MJ, Ghazzal Z, Martin JL, White J, Topol EJ. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET Trial. *Journal of the American College of Cardiology* 2003;42:981-988. PMID: 13678916
128. Saw J, Kereiakes DJ, Mahaffey KW, Applegate RJ, Braden GA, Brent BN, Brodie BR, Groce JB, Levine GN, Leya F, **Moliterno DJ**. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. *Thrombosis Research* 2003;112:301-306. PMID: 15041274
129. Saw J, **Moliterno DJ**. Contemporary use of antiplatelet therapies in percutaneous coronary interventions. *Coronary Artery Disease* 2003;14:373-380. PMID: 12878902
130. Schoenhagen P, Tuzcu EM, Stillman AE, **Moliterno DJ**, Halliburton SS, Kuzmiak SA, Kasper JM, Magyar WA, Lieber ML, Nissen SE, White RD. Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound. *Coronary Artery Disease* 2003;14:459-462. PMID: 12966267

131. Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FWA, Berger P, **Moliterno DJ**, White HD, Ohman EM, Van de Werf F, Topol EJ, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY Trials). *American Journal of Cardiology* 2003;92:330-333. PMID: 12888148
132. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van de Werf F, White JA, **Moliterno DJ**, Topol EJ. Association between admission white blood cell count and 1-year mortality in patients with acute coronary syndromes. *American Journal of Medicine* 2003;115:318-321. PMID: 12967697
133. Asher CR, **Moliterno DJ**, Bhapkar MV, McGuire DK, Rao SV, Holmes DR, Newby LK, Bates ER, Topol EJ for the SYMPHONY and 2nd SYMPHONY Investigators. Association of race with complications and prognosis following acute coronary syndromes. *American Journal of Cardiology* 2004;94:792-794. PMID: 15374792
134. Brener SJ, **Moliterno DJ**, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: Analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation* 2004;110:994-998. PMID: 15302778
135. Casserly IP, Kereiakes DJ, Gray WA, Gibson PH, Lauer MA, Reginelli JP, **Moliterno DJ**. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. *Thrombosis Research* 2004;113:115-121. PMID: 15115666
136. Casserly IP, **Moliterno DJ**. Diabetes and coronary revascularization—defining optimal revascularization modality and adjunctive medical treatment. *ACC Current Journal Review* 2004;13:71-76. PMID: n/a
137. Das P, **Moliterno DJ**. Fractionating heparins and their clinical trial data—something for everyone. *Journal of the American Medical Association* 2004;292:101-103. PMID: 15238598
138. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, **Moliterno DJ**, Raymond RE, Tuzcu EM, Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ. Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. *Catheterization and Cardiovascular Interventions* 2004;63:135-140. PMID: 15390245
139. Exaire JE, Dauerman HL, Topol EJ, Blankenship JC, Wolski K, Raymond RE, Cohen EA, **Moliterno DJ** for the TARGET Investigators. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. *American Heart Journal* 2004;147:31-34. PMID: 14691415
140. Kapadia SR, **Moliterno DJ**. Did we enjoy the debate, but forget the patient? *Journal of the American College of Cardiology* 2004;44:775-777. PMID: 15312857
141. Lee DS, Bhatt DL, **Moliterno DJ**, Peacock WF, Ellis SG, Topol EJ. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. *Journal of Invasive Cardiology* 2004;16:46-51. PMID: 14760188

142. McCarthy JJ, Parker A, Salem R, **Moliterno DJ**, Wang Q, Plow EF, Rao, S. Large scale association analysis for identification of genes underlying premature coronary artery disease: cumulative perspective from analysis of 111 candidate genes. *Journal of Medical Genetics* 2004;41:334-341. PMID: 15121769
143. McGuire DK, Newby LK, Bhapkar MV, **Moliterno DJ**, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalán R, Dellborg M, Granger CB, Van de Werf F, Topol EJ, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes: findings from the SYMPHONY and 2nd SYMPHONY studies. *American Heart Journal* 2004;147:246-252. PMID: 14760321
144. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, **Moliterno DJ**, Topol EJ, and Ardissino D. Thrombocytopenia caused by abciximab or tirofiban, and its association with clinical outcome in patients undergoing coronary stenting. *Circulation* 2004;109:2203-2206. PMID: 15117843
145. Newby LK, Bhapkar MV, White HD, **Moliterno DJ**, Allen LaPointe NM, Kandzari DE, Verheugt FWA, Kramer JM, Armstrong PW, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. *Journal of Thrombosis and Thrombolysis* 2004;16:119-128. PMID: 15087598
146. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, **Moliterno DJ**, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *Journal of the American Medical Association* 2004;292:1555-1562. PMID: 15467057
147. Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Harrington RA, Tardiff BE, Granger CB, Ohman EM, **Moliterno DJ**, Lincoff AM, Armstrong PW, Akkerhuis KM, Simoons ML, Van de Werf F, Califf RM, Topol EJ. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. *European Heart Journal* 2004;25:313-321 PMID: 14984920
148. Saw J, Topol EJ, Steinhubl S, Brennan D, Berger, PB, **Moliterno DJ** for CREDO Investigators. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. *The American Journal of Cardiology* 2004;94:623-625. PMID: 15342293
149. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, **Moliterno DJ**, Ellis SG, Topol EJ. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. *The American Journal of Cardiology* 2004;94:358-360. PMID: 15276105
150. Wang Q, Rao S, Shen G-Q, Li L, **Moliterno DJ**, Newby LK, Rogers WJ, Cannata R, Zirzow E, Elston RC, Topol EJ. Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genomewide linkage analysis. *American Journal of Human Genetics* 2004;74(2):262-271. PMID: 14732905
151. Berger PB, Best PJM, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Topol EJ, **Moliterno DJ**. Relation of renal function to ischemic and bleeding outcomes with two different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro[®] Give Similar Efficacy Outcomes Trial (TARGET). *American Heart Journal* 2005;149:869-875. PMID: 15894970

152. Chen MS, Bhatt DL, Chew DP, **Moliterno DJ**, Ellis SG, Topol EJ. Outcomes in African Americans and whites after percutaneous coronary intervention. *American Journal of Medicine* 2005;118:1019-1025. PMID: 16164889
153. Das P, **Moliterno DJ**. Enoxaparin in clinical practice and clinical trials of non-ST-elevation acute coronary syndrome (NSTEMI-ACS). *Journal of Thrombosis and Thrombolysis* 2005;19:105-113. PMID: 16052301
154. Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, **Moliterno DJ** for the ELECT Investigators. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors and clopidogrel. *Catheterization and Cardiovascular Interventions* 2005;64:369-372. PMID: 15736260
155. Ferraris VA, Ferraris SP, **Moliterno DJ**, Camp P, Walenga JM, Messmore HL, Jeske WP, Edwards FH, Royston D, Shahian DM, Peterson E, Despotis G. The Society of Thoracic Surgeons practice guidelines series: aspirin and other antiplatelet agents during operative coronary revascularization (Executive Summary). *Annals of Thoracic Surgery* 2005;79:1454-1461. PMID: 15797109
156. Gombert-Maitland M, Murphy SA, **Moliterno DJ**, Cannon CP. Are we appropriately triaging patients with unstable angina? *American Heart Journal* 2005;149:613-618. PMID: 15990742
157. Gurjeva OS, Roe M, Murphy SA, **Moliterno DJ**, Cannon CP for GUARANTEE Investigators. Unfortunate impact of age on the management and outcomes of unstable angina and non-ST-elevation myocardial infarction (GUARANTEE Registry). *Critical Pathways in Cardiology* 2005;4:81-87. PMID: 18340189
158. Justice LT, Dauterman K, Smedira NG, **Moliterno DJ**. Left main dissection and thrombosis in a young athlete. *Cardiology in Review* 2005;13:260-262. PMID: 16106188
159. Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, **Moliterno DJ**, Van de Werf F, Simes J, White HD, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of 3 randomized clinical trials. *European Heart Journal* 2005;26:128-136. PMID: 15618068
160. Mehta RH, Califf RM, Garg J, Pieper KS, Alexander J, **Moliterno DJ**, Van de Werf F, Ohman EM, White H, Topol EJ, Granger CB. Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. *American Journal of Cardiology* 2005;95:1371-1375. PMID: 15904648
161. **Moliterno DJ**. Healing Achilles—sirolimus versus paclitaxel. *New England Journal of Medicine* 2005;353:724-727. PMID: 16105991
162. **Moliterno DJ**, Steinhubl SR. Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both? *Journal of the American Medical Association* 2005;294:1271-1273. PMID: 16143697
163. **Moliterno DJ**. Letter to the editor. Drug-eluting coronary stents. *New England Journal of Medicine* 2005;353:2407-2408. Letter.

164. Mukherjee D, Topol EJ, Bertrand ME, Dalby-Kristensen S, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure R, Stone GW, Ardissino D, **Moliterno DJ** for the TARGET Investigators. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do Tirofiban and ReoPro® Give Similar Efficacy Outcomes at Trial (TARGET) 1-year follow-up. *European Heart Journal* 2005;26:2524-2528. PMID: 16107485
165. Ohman EM, Granger CB, Rice L, Abrams CS, Becker RC, Berger PB, Kleiman NS, **Moliterno DJ**, Moll S, Rogers J, Steinhubl SS, Tapson VF, Sinnaeve P, Anstrom K. Identification, diagnosis, and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. *Journal of Thrombosis and Thrombolysis* 2005;19:11-19. PMID: 15976962
166. Reddan DN, Szczech L, Bhapkar MV, **Moliterno DJ**, Califf RM, Ohman EM, Berger PB, Hochman JS, Van de Werf F, Harrington RA, Newby LK for the SYMPHONY and 2nd SYMPHONY Investigators. Renal function, concomitant medication use and outcomes following acute coronary syndromes. *Nephrology Dialysis Transplantation* 2005;20:2105-2112. PMID: 16030030
167. Steinhubl SR, Charnigo R, **Moliterno DJ**. Editorial: Resistance to antiplatelet resistance: is it justified? *Journal of the American College of Cardiology* 2005;45:1757-1758. PMID: 15936601
168. Steinhubl SR, **Moliterno DJ**. The role of the platelet in the pathogenesis of atherothrombosis. *American Journal of Cardiovascular Drugs* 2005;5:399-408. PMID: 16259528
169. Alexander KP, Newby LK, Bhapkar MV, White HD, Hochman JS, Pfisterer ME, **Moliterno DJ**, Peterson ED, Van de Werf F, Armstrong PW, Califf RM for the SYMPHONY and 2nd SYMPHONY Investigators. International variation in invasive care of the elderly with acute coronary syndromes. *European Heart Journal* 2006;27:1558-1564. PMID: 16760200
170. Das P, **Moliterno DJ**, Charnigo R, Mukherjee D, Steinhubl SR, Sneed JD, Booth DC, Ziada KM. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. *Journal of Invasive Cardiology* 2006;18:405-408. PMID: 16954577
171. Das P, Ziada K, Steinhubl SR, **Moliterno DJ**, Hamdalla H, Jozic J and Mukherjee D. Heparin-induced thrombocytopenia and cardiovascular diseases. *American Heart Journal* 2006;152:19-26. PMID: 16824828
172. Hamdalla H, **Moliterno DJ**. Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. *Expert Opinion in Pharmacotherapy* 2006;7:1669-1673. PMID: 16872270
173. Hernandez AV, Westerhout CM, Steyerberg EW, Ioannidis JPA, Bueno H, White H, Theroux P, **Moliterno DJ**, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST-segment-elevation acute coronary syndromes: benefit and harm in different age subgroups. *Heart* 2006;93:450-455. PMID 17065179

-
174. Martin JL, Jia G, Martin SS, Shapiro TA, Herrmann HC, DiBattiste PM, Topol EJ, **Moliterno DJ**. Relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. *Catheterization and Cardiovascular Interventions* 2006;67:563-570. PMID: 16532491
 175. **Moliterno DJ**. Editorial: Imminent extinction of brachy(saurus)therapy for the treatment of in-stent restenosis. *Catheterization and Cardiovascular Interventions* 2006;68:349-351. PMID: 16894576
 176. Mukherjee D, **Moliterno DJ**. Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. *Journal of the American Medical Association* 2006;295:1307-1309. PMID: 16531620
 177. **Moliterno DJ**. Editorial: Randomized trial versus registry data—comparing apples and ORCHIDs. *Catheterization and Cardiovascular Interventions* 2006;68:669-670. PMID: 17039505
 178. Mukherjee D, Topol EJ, **Moliterno DJ**, Brennan DM, Ziada K, Cho L, Steinhubl SR. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. *Heart* 2006;92(1):49-51. PMID: 15845611
 179. Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, **Moliterno DJ**, Lincoff AM, Armstrong PW, van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. *Journal of the American College of Cardiology* 2006;47:809-816. PMID: 16487850
 180. Saw J, Bhatt D, **Moliterno DJ**, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in 8 large randomized percutaneous coronary intervention trials. *Journal of the College of Cardiology* 2006;48:1567-1572 PMID: 17045889
 181. Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, Stone GW, McClure R, Roffi M, **Moliterno DJ** for the TARGET Investigators. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. *American Journal of Cardiology* 2006;97:1585-1590. PMID: 16728219
 182. Westerhout CM, Hernandez AV, Steyerberg EW, Bueno H, White H, Theroux P, **Moliterno DJ**, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. Predictors of stroke within 30 days in patients with non-ST-segment-elevation acute coronary syndromes. *European Heart Journal* 2006;27:2956-2961. PMID: 17093039
 183. Dove JT, **Moliterno DJ**, Weaver WD, Shelton ME. President's Page: Drug-eluting stents in contemporary practice—a call for a real-world, open-entry, device-tracking registry. *Journal of the American College of Cardiology* 2007;49:2223-2226. PMID: 17543645
 184. Grines CL, Bonow RO, Casey DE, Gardner T, Lockhart PB, **Moliterno DJ**, O’Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A Science Advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with Representation from the American College of Physicians. *Catheterization and Cardiovascular Interventions* 2007;69:334-340 PMID: 17295287 | *Journal of the American College of Cardiology* 2007;49:734-739 PMID: na | *Circulation* 2007;115:813-818 PMID: 17224480 | *Journal of the American Dental Association* 2007;185:652-655. PMID: 17473044
-

185. Hernandez AV, Westerhout CM, Ioannidis JPA, Styerberg EW, Bueno H, White H, Theroux P, **Moliterno DJ**, Armstrong PW, Califf RM, Topol EJ, Wallentin LC, Simoons ML, Boersma E. Effects of platelet glycoprotein IIb/IIIa inhibitors in non-ST-segment-elevation acute coronary syndromes: Benefits and harm in different age subgroups. *Heart* 2007;93:450-455. PMID: 17065179
186. Kalyanasundaram A, Blankenship JC, Berger P, Herrmann H, McClure R, **Moliterno DJ**. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (Do Tirofiban and ReoPro® Give Similar Efficacy?) trial. *Catheterization and Cardiovascular Interventions* 2007;69:623-629. PMID: 17192960
187. Mardikar HM, Hiremath MS, **Moliterno DJ**, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande NV, Khan A, Joseph J, and Mukherjee D. Optimal platelet inhibition in patients undergoing PCI: Data from the Multi-center Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR-PCI) Study. *American Heart Journal* 2007;154:344.e1-5. PMID: 17643586
188. **Moliterno DJ**. Editorial: The challenge of qualifying exceedingly rare occurrences—we can only see what we see. *Catheterization and Cardiovascular Interventions* 2007;69:719-720. PMID: 17390302
189. **Moliterno DJ**. Editorial: Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stents. *Catheterization and Cardiovascular Interventions* 2007;69:799-800. PMID: 17377984
190. **Moliterno DJ**, Campbell CL. Editorial: Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag. *Journal of the American College of Cardiology* 2007;49:2318-2319. PMID: 17572246
191. Mukherjee D, **Moliterno DJ**. The timely coupling of mechanical revascularization following thrombolysis for myocardial infarction. *Cardiology* 2007;107:337-339 PMID: 17268199
192. Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, **Moliterno DJ**, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? *Journal of the American College of Cardiology* 2007;49:849-854. PMID: 17320742
193. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, **Moliterno DJ**, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *American Journal of Gastroenterology* 2008 103:2890-2907. PMID: 18853965 | *Circulation* 2008;52:1502-17. PMID 19017521
194. Brener SJ, **Moliterno DJ**, Aylward PE, van't Hof AWJ, Ruzyllo W, O'Neill WW, Hamm CW, Westerhout CM, Granger CB, Armstrong PW for the APEX-AMI Investigators. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. *European Heart Journal* 2008; 29:1127-1135. PMID: 18375399

195. Hamdalla H, **Moliterno DJ**. Editorial: Late drug-eluting stent thrombosis of unprotected left main coronary artery lesions—sometimes possible but rarely definite or probable. *European Heart Journal* 2008. PMID: 18664463
196. **Moliterno DJ**. Advances in antiplatelet therapy for ACS and PCI. *Journal of Interventional Cardiology* 2008;21:S18-24. PMID: 19090933
197. **Moliterno DJ**. Editorial: Late target lesion revascularization following drug-eluting stents—looking back and forward to success. *Catheterization and Cardiovascular Interventions* 2008;71:304-305. PMID: 18288752
198. **Moliterno DJ**. Late percutaneous recanalization of totally occluded infarct-related arteries—more than about time. *Catheterization and Cardiovascular Interventions* 2008;71:782-783. PMID: 18415953
199. **Moliterno DJ**. Racial differences in outcome following percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions* 2008;72:45-46. PMID: n/a
200. **Moliterno DJ**, Ziada KM. Editorial: The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. *Journal of the American College of Cardiology* 2008;51:536-537. PMID: 18237681
201. Mukherjee D, **Moliterno DJ**. Effectiveness of drug-eluting stents in real-world patients. *Journal of the American Medical Association* 2008;299:454-455. PMID: 1823075
202. Novaro GM, Asher CR, Bhatt DL, **Moliterno DJ**, Harrington RA, Lincoff AM, Newby LK, Tchong JE, Hsu AP, Pinski SL. Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus Whites. *American Journal of Cardiology* 2008;101:506-509. PMID: 18312767
203. Oliveira GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, **Moliterno DJ**, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman M, Granger CB for the CATCH Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. *Archives of Internal Medicine* 2008;168:94-102. PMID: 18195201
204. Salah AK, Ahmed A, Bodiwala KN, Manaloor EJ, Thornton JW, **Moliterno DJ**. Cardiac amyloidosis. *Canadian Journal of Cardiology* 2008;24(5):e35. PMID: 18464954
205. Salah A, **Moliterno DJ**, Humphries R, Syed MA. Role of cardiac computed tomography and magnetic resonance imaging in the evaluation of acute chest pain in the emergency department. *International Journal of Cardiovascular Imaging* 2008;24:331-342. PMID: 17849234
206. Abdel-Latif A, **Moliterno DJ**. Antiplatelet polypharmacy in primary percutaneous coronary intervention: trying to understand when more is better. *Circulation* 2009;119:3168-3170. PMID: 19528332
207. Abdel-Latif A, **Moliterno DJ**. Prasugrel versus clopidogrel in primary PCI: considerations of the TRITON-TIMI 38 substudy. *Current Cardiology Reports* 2009;11:323-324. PMID: 19709491

208. Becker RC, **Moliterno DJ**, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. *The Lancet* 2009;373:919-928. PMID: 19286091
209. Brener SJ, Westerhout CM, Fu Y, Todaro TG, **Moliterno DJ**, Wagner GS, Granger CB, Armstrong PW; APEX-AMI Investigators. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. *American Heart Journal* 2009;158:755-760. PMID: 19853693
210. Crespo EM, Oliveira GB, Honeycutt EF, Becker RC, Berger PB, **Moliterno DJ**, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Granger CB, Ohman EM; CATCH Registry Investigators. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. *American Heart Journal* 2009;157:651-657. PMID: 19332191
211. Holmes DR Jr, Kereiakes DJ, Kleiman NS, **Moliterno DJ**, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. *Journal of the American College of Cardiology* 2009;54:95-109. PMID: 19573725
212. Jolicoeur EM, Ohman EM, Honeycutt E, Becker RC, Crespo EM, Oliveira GBF, **Moliterno DJ**, Anstrom KJ, and Granger CB. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. *American Journal of Cardiology* 2009;104:292-297. PMID: 19576363
213. Koul S, **Moliterno DJ**. Editorial: Bare-metal versus drug-eluting stent placement among patients presenting with anemia. *Journal of the American College of Cardiology* 2009;2:337-338. PMID: 19463446
214. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, **Moliterno DJ**, Nassif D, Lopez JJ, Saucedo JF; on behalf of the EVENT Investigators. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry. *Journal of the American College of Cardiology* 2009;2:37-45. PMID: 19463396
215. Lopes RD, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GB, Moll S, **Moliterno DJ**, Abrams CS, Becker RC. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation: The Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. *American Journal of Cardiology* 2009;104:1285-1291. PMID: 19840578

216. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, **Moliterno DJ**, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009;119:2250-2294. PMID: 19332472
217. **Moliterno DJ**. Left main and multivessel coronary artery stenting for patients deemed inoperable—a real need for a tandem approach. *Catheterization and Cardiovascular Interventions* 2009;74:311-312. PMID: 19642179
218. **Moliterno DJ**. Trifurcation left main coronary artery percutaneous revascularization—pushing catheters and envelopes. *Catheterization and Cardiovascular Interventions* 2009;73:32-33. PMID: 19089933
219. Mukherjee D, **Moliterno DJ**. Effectiveness of PCI for non-acute coronary artery disease. *The Lancet* 2009;373:870-872. PMID: 19286067
220. Mukherjee D, **Moliterno DJ**. Second-generation drug-eluting stents and the continuous need for rapidly available real world data. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2009;2:1236-1239. PMID: 20129550
221. Rajan L, **Moliterno DJ**. Editorial: Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention. *European Heart Journal* 2009;30:1687-1689. PMID: 19429914
222. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, **Moliterno DJ**, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2009;29:449-457. PMID: 19023091
223. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, **Moliterno DJ**, Van de Werf F, White HD, Harrington RA, Roe MT. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) undergoing diagnostic angiography. *American Heart Journal* 2009;157:716-723. PMID: 19332201
224. Abdel-Latif A, **Moliterno DJ**. Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis—When a Rare Disorder Can Predispose to Rare Events. *Journal of Interventional Cardiology* 2010;23:565-568. PMID: 20796164

225. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, Harrington RA, Bates ER, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Hlatky MA, Jacobs AK, Kaul S, **Moliterno DJ**, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *Journal of the American College of Cardiology* 2010;56:2051-2066. PMID: 21126648
 226. George JC, **Moliterno DJ**, Dangas GD. American College of Cardiology Annual Scientific Session 2010: update in interventional cardiology *Journal of the American College of Cardiology: Cardiovascular Interventions* 2010;3:562-564. PMID: 20488415
 227. Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, Williams DO, Kimura T, **Moliterno DJ**. Stent thrombosis. *Journal American College of Cardiology* 2010;56:1357-1365. PMID: 20946992
 228. Means RT Jr, **Moliterno DJ**, Allison GR, Perman JA, Lofgren RP, Karpf M, Debeer FC. The evolution of a department of internal medicine under an integrated clinical enterprise model: the University of Kentucky experience. *Academic Medicine* 2010;85:531-537. PMID: 20182134
 229. **Moliterno DJ**. Rotational atherectomy for resistant chronic total occlusions: another spin for tough old problems. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2010;76:372-373. PMID: 20839350
 230. Tackett AH, Bailey AL, Foody JM, Miller JM, Apperson-Hansen C, Ohman EM, Hochman JS, Karnash SL, Califf RM, Topol EJ, **Moliterno DJ**. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. *American Heart Journal* 2010;160:678-684. PMID: 20934562
 231. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AWJ, Campo G, Hamm C, Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, **Moliterno DJ**, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. *European Heart Journal* 2010;31:35-49. PMID: 19755402
 232. Wiisanen ME, **Moliterno DJ**. The use of single versus dual antiplatelet therapy beyond 1 year following drug-eluting stent implantation. *Current Cardiology Reports* 2010;12:357-360. PMID: 20544309
 233. Anaya P, **Moliterno DJ**. Patient, Heal Thyself: The Ongoing Evolution of Patient Self-directed Care and Hand-Held Technology. *Annals of Internal Medicine* 2011;154:500-501. PMID: 21464353
 234. Elayi CS, Whitbeck MG, Charnigo R, Shah J, Macaulay TE, Morales G, Gurley JC, Kakavand B, Thal S, Ching CK, Khaykin Y, Verma A, Barrett C, Bai R, Di Biase L, Patwardhan A, **Moliterno DJ**, Natale A. Is there an Association Between External Cardioversions and Long Term Mortality and Morbidity - Insights from the AFFIRM Study. *Circulation, Arrhythmia and Electrophysiology* 2011;4:465-469. PMID: 21511994
 235. **Moliterno DJ**. ACP Journal Club: Increased doses of clopidogrel or aspirin did not prevent cardiovascular events. *Annals of Internal Medicine* 2011;154:JC1-7. PMID: 21242361
-

236. **Moliterno DJ.** Unfractionated versus low-molecular-weight heparin for primary angioplasty – More data suggesting to go low. *Catheterization and Cardiovascular Interventions* 2011;77:191-192. PMID: 21290553
237. **Moliterno DJ,** TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. *Catheterization and Cardiovascular Interventions* 2011;77:1001-1009. PMID: 21598351
238. Elayi CS, Allen CL, Leung S, Lusher S, Morales GX, Wiisanen M, Aikat S, Kakavand B, Shah JS, **Moliterno DJ,** Gurley JC. Inside-out access: a new method of lead placement for patients with central venous occlusions. *Heart Rhythm.* 2011;8:851-857. PMID: 21237290
239. Rajan L, **Moliterno DJ.** Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS? *Current Cardiology Reports* 2011. PMID: 21607650
240. Ziada KM, Charnigo R, **Moliterno DJ.** Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2011;4:39-41. PMID: 21251627
241. Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Thérroux P, Stone GW, **Moliterno DJ,** Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA. Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials. *Circulation: Cardiovascular Quality and Outcomes.* 2011;4:448-458. PMID: 21712522
242. Wallace EL, **Moliterno DJ.** The Use of Drug-Eluting Stents Versus Bypass Surgery for Left Main Coronary Artery Disease. *Current Cardiology Reports* 2011. PMID: 21735107
243. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, **Moliterno DJ,** Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *Journal of the American Society of Hypertension.* 2011;5:259-352. PMID: 21771565

244. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, **Moliterno DJ**, Becker RC, Angiolillo DJ. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. *Thrombosis and Haemostasis* 2011;106. PMID: 21785808
245. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, **Moliterno DJ**, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a north american perspective: executive summary. *Circulation: Cardiovascular Interventions* 2011;4:522-534. PMID: 22010191
246. Tricoci P, Huang Z, Held C, **Moliterno DJ**, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; the TRACER Investigators. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. *New England Journal of Medicine* 2012;366:20-33. PMID: 22077816
247. Kristensen SD, Würtz M, Grove EL, De Caterina R, Huber K, **Moliterno DJ**, Neumann FJ. Contemporary Use of Glycoprotein IIb/IIIa Inhibitors. *Thrombosis and Haemostasis* 2012;107:215-224. PMID: 22234385
248. Wallace EL, Abdel-Latif A, Charnigo R, **Moliterno DJ**, Brodie B, Matnani R, Ziada KM. Meta-Analysis of Long-Term Outcomes for Drug-Eluting Stents Versus Bare-Metal Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction. *American Journal of Cardiology* 2012;109:932-940. PMID: 22221949
249. Abdel-Latif A, **Moliterno DJ**. Creating biodegradable-polymer drug-eluting stents: shortening the duration of polymer and dual antiplatelet therapy while lengthening the follow-up. *Catheterization and Cardiovascular Interventions* 2012;79:217-218. PMID: 22271552
250. Holmes DR, Mack MJ, Kaul S, Agnihotri A, Kappetein AP, Alexander KP, Linderbaum JA, Bailey SR, Mukherjee C, Calhoon JH, Mukherjee D, Carabello BA, Otto CM, Desai MY, Ruiz CE, Edwards FH, Sacco RL, Francis GS, Smith D, Gardner TJ, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Hernandez AF, Fisher JD, Jacobs AK, Garcia MJ, Kaul S, Gardner TJ, Linderbaum JA, Gentile F, **Moliterno DJ**, Gilson MF, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Catheterization and Cardiovascular Interventions* 2012;79:1023-1082 PMID: 22294439
251. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, **Moliterno DJ**, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. *Journal of Thrombosis and Thrombolysis* 2012;34:106-113. PMID: 22307842

252. Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, **Moliterno DJ**, Thérroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. *International Journal of Cardiology* 2012;167:548-554. PMID: 22341697
253. Foley JD 3rd, **Moliterno DJ**. Contemporary occurrence of stent thrombosis in clinical practice: better never than late. *Catheterization and Cardiovascular Interventions* 2012;79:557-558. PMID: 22344988
254. Bashore TM, Balter S, Barac A, Byrne JG, Cavendish JJ, Chambers CE, Hermiller JB Jr, Kinlay S, Landzberg JS, Laskey WK, McKay CR, Miller JM, **Moliterno DJ**, Moore JW, Oliver-McNeil SM, Popma JJ, Tommaso CL. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update: a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Journal of the American College of Cardiology* 2012;59:2221-2305. PMID: 22575325
255. Bashore TM, Balter S, Barac A, Byrne JG, Cavendish JJ, Chambers CE, Hermiller JB Jr, Kinlay S, Landzberg JS, Laskey WK, McKay CR, Miller JM, **Moliterno DJ**, Moore JW, Oliver-McNeil SM, Popma JJ, Tommaso AC, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner T, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Weitz HH, Wesley DJ. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update: American College of Cardiology Foundation Task Force on Expert Consensus Documents Society of Thoracic Surgeons Society for Vascular Medicine. *Catheterization and Cardiovascular Interventions* 2012;80:E37-49. PMID: 22570114
256. Rajan L, **Moliterno DJ**. New anticoagulants in ischemic heart disease. *Current Cardiology Reports* 2012;14:450-456. PMID: 22528556
257. Wiisanen ME, **Moliterno DJ**. Platelet protease-activated receptor antagonism in cardiovascular medicine. *Coronary Artery Disease* 2012;23:375-379. PMID: 22781741
258. Capodanno D, Bhatt DL, Goto S, O'Donoghue ML, **Moliterno DJ**, Tamburino C, Angiolillo DJ. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. *Journal of Thrombosis and Haemostasis*. 2012;10:2006-2015. PMID: 22845871
259. Anaya P, **Moliterno DJ**. CT Angiography for Emergency Decision Making in Acute Coronary Syndromes: Applying Future Vision Now. *Current Cardiology Reports* 2012;14:537-539. PMID: 22890753
260. Dunn SP, Holmes DR Jr, **Moliterno DJ**. Drug-drug interactions in cardiovascular catheterizations and interventions. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2012;5:1195-1208. PMID: 23257367
261. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, **Moliterno DJ**, Elayi CS. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. *European Heart Journal* 2012;34:1481-1488. PMID: 23186806

262. Kalra N, **Moliterno DJ**. Zotarolimus-eluting stents among patients with renal impairment undergoing percutaneous coronary intervention. *Catheterizations Cardiovascular Interventions* 2012;80:893-894. PMID: 23166098
263. El Mallah W, **Moliterno DJ**. Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement. *Catheterizations Cardiovascular Interventions* 2012;80:406-407. PMID: 22933348
264. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Fisher JD, Garcia MJ, Gardner TJ, Gentile F, Gilson MF, Hernandez AF, Jacobs AK, Kaul S, Linderbaum JA, **Moliterno DJ**, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Journal of Thoracic and Cardiovascular Surgery* 2012;144:e29-84. PMID: 22898522
265. van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, **Moliterno DJ**, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; on behalf of the APEX AMI Investigators. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. *International Journal of Cardiology* 2013;S0167-5273:00019-3. PMID: 23394896
266. Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, **Moliterno DJ**, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. *European Heart Journal* 2013;34:1723-1731. PMID: 23530022
267. Abdel-Latif A, **Moliterno DJ**. Remote ischemic preconditioning in elective percutaneous coronary intervention does not protect myocardium nor mobilize endothelial progenitor cells. *Catheterizations Cardiovascular Interventions* 2013;81:937-938. PMID: 23606488
268. **Moliterno DJ**, Smyth SS. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. *Heart* 2013;99:1305-1306. PMID: 23697653
269. Rajan L, **Moliterno DJ**. Stent thrombosis through the generations. *The Journal of Invasive Cardiology* 2013;25:337-338. PMID: 23813061
270. Campbell CL, **Moliterno DJ**. The Value of High-Sensitivity Troponin in Assessing the Extent of Benefit Provided by Ticagrelor versus Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndromes. *Circulation* 2013;129:278-280. PMID: 24170389
271. Anaya P, **Moliterno DJ**. The evolving role of cardiac troponin in the evaluation of cardiac disorders. *Current Cardiology Reports* 2013;15:420. PMID: 24057774

-
272. Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, **Moliterno DJ**, de Werf FV, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial. *Journal of the American College of Cardiology* 2014;63:1048-1057. PMID: 24211500
273. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, **Moliterno DJ**, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 2013;382:1714-1722. PMID: 24004642
274. Whitbeck MG, Charnigo RJ, Shah J, Morales G, Leung SW, Fornwalt B, Bailey AL, Ziada K, Sorrell VL, Zegarra MM, Thompson J, Hosn NA, Campbell CL, Gurley J, Anaya P, Booth DC, Biase LD, Natale A, Smyth S, **Moliterno DJ**, Elayi CS; the AFFIRM investigators. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. *Europace* 2014;16:803-811. PMID: 24368753
275. Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, **Moliterno DJ**, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). *American Journal of Cardiology* 2014;113:936-944. PMID: 24444781
276. Storey RF, Kotha J, Smyth S, **Moliterno DJ**, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. *Thrombosis and Haemostasis* 2014;111:883-891. PMID: 24402559
277. Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, **Moliterno DJ**, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. *European Heart Journal Acute Cardiovascular Care*. 2014;3:246-256. PMID: 24627331
278. Ruiz-Rodriguez E, **Moliterno DJ**. High-risk coronary anatomy versus high-risk physiology as outcome predictors in acute coronary syndromes. *Catheterization Cardiovascular Interventions*. 2014;83:684-685. PMID: 24638944
279. Judge HM, Jennings LK, **Moliterno DJ**, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J, Storey RF. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. *Platelets*. 2015;26:236-242. PMID: 24750101
280. Bhatt DL, Hulot JS, **Moliterno DJ**, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. *Circulation Research* 2014;114:1929-43. PMID: 24902976
-

281. Ziada K, **Moliterno DJ**. Revascularization for patients with stable coronary artery disease. *British Medical Journal* 2014;23:348. PMID: 24958028
282. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, **Moliterno DJ**, Aylward PE, Mahaffey KW, Armstrong PW. Reduction in overall occurrences of ischemic events with vorapaxar: results from Tracer. *Journal of the American Heart Association* 2014;3:e001032. PMID: 25012288
283. Randall MH, **Moliterno DJ**. The impact of left anterior descending coronary artery length on survival following myocardial infarction: the apex and beyond. *Catheterization Cardiovascular Interventions* 2014;84:321-322. PMID: 25045098
284. Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, **Moliterno DJ**. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from TRACER Trail). *American Journal of Cardiology* 2015;114:665-673. PMID: 25129064
285. Jones WS, Tricoci P, Huang Z, **Moliterno DJ**, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). *American Heart Journal* 2014;168:588-596. PMID: 25262270
286. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, **Moliterno DJ**, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. *American Heart Journal* 2014;168:869-877. PMID: 25458650
287. Campbell CL, **Moliterno DJ**. Potential hazards of adding nonsteroidal anti-inflammatory drugs to antithrombotic therapy after myocardial infarction: time for more than a gut check. *Journal of the American Medical Association* 2015;313:801-802. PMID: 25710655
288. Cornel JH, Tricoci P, Lokhnygina Y, **Moliterno DJ**, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). *American Journal of Cardiology* 2015; 115:1325-1332. PMID: 25776457
289. Abdel-Latif A, **Moliterno DJ**. Bifurcation stenting techniques and outcomes in patients with stable coronary artery disease: more evidence suggesting simpler is safer. *JACC Cardiovascular Interventions* 2015;8:561-563. PMID: 25907083
290. Kragholm K, Halim SA, Yang Q, Schulte PJ, Hochman JS, Melloni C, Mahaffey KW, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Ohman EM, Van de Werf F, Tricoci P, Alexander JH, Giugliano RP, Newby LK. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. *Circulation Cardiovascular Quality Outcomes* 2015;8:357-367. PMID: 26152683

291. Ziada KM, Abdel-Latif A, Charnigo R, **Moliterno DJ**. Safety of an abbreviated duration of dual antiplatelet therapy (≤ 6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. *Catheterization Cardiovascular Interventions* 2016;87:722-732. PMID: 26309050
292. Kim SM, **Moliterno DJ**. Ageless benefits of transradial access for percutaneous coronary revascularization. *Catheterization Cardiovascular Interventions* 2015;86:973-974. PMID: 26541798
293. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, **Moliterno DJ**, White HD, Mahaffey KW, Harrington RA, Armstrong PW. Efficacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. *Journal of the American Heart Association* 2015;4. PMID: 26672080
294. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, **Moliterno DJ**, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Arterial access and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. *Catheterization Cardiovascular Interventions* 2016;88:163-173. PMID: 26698636
295. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, **Moliterno DJ**, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. *Journal of the American College of Cardiology* 2016;67:2224-2234. PMID: 27079334
296. Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, **Moliterno DJ**, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzyllo W, Harrington RA, Tricoci P. Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial. *Journal of the American College of Cardiology* 2016;67:2135-2144. PMID: 27151345
297. Popma CJ, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, **Moliterno DJ**, White HD, Van de Werf F, Harrington RA, Wallentin L, Held C, Armstrong PW, Aylward PE, Strony J, Mahaffey KW, Gibson CM. Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy. *Circulation Cardiovascular Interventions* 2016. PMID: 27162212
298. Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, **Moliterno DJ**, Weisz G, Colombo A, Pocock S, Mehran R. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. *JACC Cardiovascular Interventions* 2016;9:1349-57. PMID: 27388822
299. Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, **Moliterno DJ**, Colombo A, Pocock S, Mehran R. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. *JACC Cardiovascular Interventions* 2016;9:1461-9. PMID: 27478113

300. Åkerblom A, Clare RM, Lokhnygina Y, Wallentin L, Held C, Van de Werf F, **Moliterno DJ**, Patel UD, Leonardi S, Armstrong PW, Harrington RA, White HD, Aylward PE, Mahaffey KW, Tricoci P. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. *American Heart Journal*. 2016;178:1-8. PMID: 27502846
301. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, **Moliterno DJ**, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. *American Heart Journal* 2016;178:176-84. PMID: 27502866
302. Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, **Moliterno DJ**, Mahaffey KW, Tricoci P. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. *JAMA Cardiology* 2016;1:73-79. PMID: 27437658
303. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, **Moliterno DJ**, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. *Circulation: Cardiovascular Interventions* 2016;9 Review. PMID: 27803042
304. Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, **Moliterno DJ**, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. *European Journal of Acute Cardiovascular Care* 2017;6:155-163. PMID: 26895973
305. Chandrasekhar J, Bansilal S, Baber U, Sartori S, Aquino M, Farhan S, Vogel B, Faggioni M, Giustino G, Ariti C, Colombo A, Chieffo A, Kini A, Saporito R, Michael Gibson C, Witzenbichler B, Cohen D, **Moliterno DJ**, Stuckey T, Henry T, Pocock S, Dangas G, Gabriel Steg P, Mehran R. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. *Catheterization Cardiovascular Interventions* 2017;88:E217-E225. PMID: 27650638
306. **Moliterno DJ**. Research Correspondence: One Good Point, One Great Figure (or Table). *JACC Cardiovascular Interventions* 2017;10:2347-2348. PMID: 29169508
307. **Moliterno DJ**, Ziada KM. More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents: Related Versus Unrelated Events. *Journal of the American College of Cardiology* 2017;69:625-627. PMID: 28183506
308. Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. *JACC Cardiovascular Interventions* 2017;10:645-654. PMID: 28330641

309. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, **Moliterno DJ**, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *European Heart Journal* 2017;38:804-810. PMID: 28363222
310. Koshizaka M, Lopes RD, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, **Moliterno DJ**, Giugliano RP, Huber K, James S, Harrington RA, Alexander JH. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. *American Journal of Medicine* 2017;130:1170-1176. PMID: 28396226
311. **Moliterno DJ**. A Letter to the (Founding) Editor: A King by Any Name. *JACC Cardiovascular Interventions* 2017;10:1378-1379. PMID: 28683945
312. **Moliterno DJ**. JACC: Cardiovascular Interventions 2.0: The Journey Begins. *JACC Cardiovascular Interventions* 2017;10:1473-1474. PMID: 28728666
313. **Moliterno DJ**. The Value of Focus. *JACC Cardiovascular Interventions* 2017;10:1603-1604. PMID: 28797442
314. **Moliterno DJ**. Be Careful What You Read and the Company You Keep. *JACC Cardiovascular Interventions* 2017;10:1715-1716. PMID: 28838484
315. **Moliterno DJ**. Little Kids, Little Problems-Big Kids, Big Problems. *JACC Cardiovascular Interventions* 2017;10:1807-1808. PMID: 28882289
316. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, **Moliterno DJ**, Colombo A, Mehran R. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). *Circulation: Cardiovascular Interventions* 2017;10:9. PMID: 28916600
317. Schoos M, Chandrasekhar J, Baber U, Bhasin A, Sartori S, Aquino M, Vogel B, Farhan S, Sorrentino S, Kini A, Kruckoff M, **Moliterno DJ**, Henry TD, Weisz G, Gibson CM, Iakovou I, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Dangas G, Pocock S, Mehran R. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). *American Journal Cardiology* 2017;120:904-910. PMID: 28778417
318. **Moliterno DJ**. One Man's Vacation, Another Man's Stress Test. *JACC Cardiovascular Interventions* 2017;10:2133-2134. PMID: 29050634
319. **Moliterno DJ**. CTO-Chronic Total Occlusions and Continuous Training Opportunity. *JACC Cardiovascular Interventions* 2017;10:2231-2232. PMID: 29122138

320. **Moliterno DJ.** The Year of Special Anniversaries: Tin, Crystal, Silver and Ruby. *JACC Cardiovascular Interventions* 2017;10:2587-2588. PMID: 29268892
321. Guimarães PO, Leonardi S, Huang Z, Wallentin L, Van de Werf F, Aylward PE, Held C, Harrington RA, **Moliterno DJ**, Armstrong PW, White HD, Alexander KP, Lopes RD, Mahaffey KW, Tricoci P, Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Trial. *American Heart Journal* 2018;196:28-35. PMID: 29421012
322. Misumida N, **Moliterno DJ.** Hybrid coronary revascularization: Time for a new comparator? *Catheter Cardiovascular Interventions* 2018;91:213-214. PMID: 29405596
323. **Moliterno DJ.** The Top Papers of 2017: By Subsequent Citations and Online Views and Downloads. *JACC Cardiovascular Interventions* 2018;11:325-327. PMID: 29413251
324. **Moliterno DJ.** The Top Papers of 2017: Editor's Pick. *JACC Cardiovascular Interventions* 2018;11:513-515. PMID: 29519391
325. **Moliterno DJ.** State-of-the-Art Papers: Gemstones. *JACC Cardiovascular Interventions* 2018;11:613-614. PMID: 29566810
326. Rymer JA, Tempelhof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Lopes RD, Mahaffey KW, Newby LK. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. *American Heart Journal* 2018;201:103-110. PMID: 29910048
327. Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, **Moliterno DJ**, Colombo A, Mehran R. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). *Circulation Cardiovascular Interventions* 2018;11:e006144. PMID: 29870385
328. **Moliterno DJ.** Images in Intervention: Icons. *JACC Cardiovascular Interventions* 2018;11:1018-1019. PMID: 29798769
329. Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, **Moliterno DJ**, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. *JACC Cardiovascular Interventions*.2018;11:856-864. PMID: 29747915
330. Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, **Moliterno DJ**, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. *Blood Cells Molecules and Diseases* 2018;72:37-43. PMID: 30055940

-
331. **Moliterno DJ.** Year 1: A Short Look Back and a Long Look Forward. *JACC Cardiovascular Interventions* 2018;1:1793-1795. PMID: 30190073
332. Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, **Moliterno DJ**, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. *Journal of the American Heart Association* 2018;7:e009609. PMID: 30526198
333. **Moliterno DJ.** Being a Great Reviewer: Remembering the “Why”. *JACC Cardiovascular Interventions* 2018;11:2130-2131. PMID: 30336820
334. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, **Moliterno DJ**, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. *Circulation*. 2018;138:527-536. PMID:30571525
335. Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). *American Journal of Cardiology* 2018;122:1638-1646. PMID: 30270177
336. Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, **Moliterno D**, Colombo A, Pocock S, Dangas G, Mehran R. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. *American Journal of Cardiology*. 2019;1;123(5):709-716. PMID:30612724
337. Moalem K, Baber U, Chandrasekhar J, Claessen BE, Sartori S, Aquino M, Dangas G, Iakovou I, Colombo A, Kini A, Gibson M, Krucoff M, Chieffo A, **Moliterno D**, Witzenbichler B, Pocock S, Mehran R. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. *Clinical Research Cardiology*. 2019;108;6:643-650. PMID: 30607496
338. Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, **Moliterno D**, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. *Circulation Cardiovascular Quality and Outcomes*. 2019;12:e004945. PMID:30606052
339. **Moliterno DJ**, Windecker S. Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals. *Journal of the American College of Cardiology* 2019;73:1353-1357. PMID:30898211
340. Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, **Moliterno DJ**, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous
-

- Coronary Intervention. *Circulation Cardiovascular Interventions* 2019;12(4):e007133. PMID: 30998384
341. Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, **Moliterno DJ**, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. *JACC Cardiovascular Interventions* 2019;27;12(10):983-992. PMID: 31122354
342. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, **Moliterno DJ**, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. *JACC Cardiovascular Interventions* 2019;26;12(16):1521-1537. PMID: 31202949
343. Ziada KM, **Moliterno DJ**. Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin? *Journal of the American Medical Association* 2019;25;321(24):2409-2411. PMID: 31237621
344. Vogel B, Chandrasekhar J, Baber U, Mastoris I, Sartori S, Aquino M, Krucoff MW, **Moliterno DJ**, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini AS, Farhan S, Sorrentino S, Faggioni M, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen DJ, Stuckey T, Ariti C, Dangas GD, Pocock S, Mehran R. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. *Journal of Thrombosis and Haemostasis* 2019;19(10):1704-1711. PMID: 31365942
345. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, **Moliterno D**, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. *New England Journal of Medicine* 2019;21;381(21):2032-2042. PMID: 31556978
346. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, **Moliterno D**, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. *European Heart Journal* 2020;41;37:3533-3545. PMID: 33085967
347. Smyth SS, **Moliterno D**, McClure R, Campbell J, Buckler L, McMullen CA, Wayne TF, Endean E, Sekela M, Karpf M. Securing the Future for a Major Academic Cardiovascular Program: Hardwiring a Referral Network and Preparing for a Transition to Value-Based Reimbursement. *Hospital Topics* 2020;98;4:163-171. PMID: 32804052
348. Whiteside HL, **Moliterno DJ**. Coronary interventions among patients with hepatic insufficiency: Encouragement to avoid a jaundiced view. *Catheterization and Cardiovascular Intervention* 2020;96;4:811-812. PMID: 33085200
-

349. **Moliterno DJ**, Smyth SS, Abdel-Latif A. CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All. *Journal of the American Medical Association* 2020;324;8:747-749. PMID: 32840581
350. Marquis-Gravel G, **Moliterno DJ**, Francis DP, Jüni P, Rosenberg YD, Claessen BE, Mentz RJ, Mehran R, Cutlip DE, Chauhan C, Quella S, Zannad F, Goodman SG. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. *Journal of the American College of Cardiology* 2020;76;4:435-450. PMID: 32703515
351. Sorrentino S, Sartori S, Baber U, Claessen BE, Giustino G, Chandrasekhar J, Chandiramani R, Cohen DJ, Henry TD, Guedeney P, Ariti C, Dangas G, Gibson CM, Krucoff MW, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Urban P, Mehran R. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. *Circulation: Cardiovascular Interventions* 2020;13;4. PMID: 32216472
352. White CJ, Samady H, **Moliterno DJ**. The Case for Mandatory COVID-19 Vaccination of Health Care Workers. *JACC Cardiovasc Interv.* 2021;14:1961-1962. PMID: 34503752
353. Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, Granger CB, Holmes DR, Lopes RD, Mehran R, **Moliterno DJ**, Price MJ, Saw J, Tanguay JF, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. *Circulation.* 2021 Feb 9;143(6):583-596. PMID: 33555916
354. Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. *JACC Cardiovascular Interventions.* 2021;14:444-456. PMID: 33602441
355. Vogel B, Baber U, Cohen DJ, Sartori S, Sharma SK, Angiolillo DJ, Farhan S, Goel R, Zhang Z, Briguori C, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Han YL, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta SR, **Moliterno D**, Ohman EM, Sardella G, Witzenbichler B, Gibson CM, Pocock S, Huber K, Mehran R. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. *JAMA Cardiology.* 2021;6:1032-1041. PMID: 33991416
356. Angiolillo DJ, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Mehta S, Briguori C, Cohen DJ, Collier T, Dudek D, Escaned J, Gibson CM, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Oldroyd K, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. *JACC Cardiovascular Interventions.* 2021;14:1434-1446. PMID: 34238553

357. Stefanini GG, Briguori C, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Angiolillo DJ, Mehta S, Cohen DJ, Collier T, Dudek D, Escaned J, Gibson CM, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Oldroyd KG, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. *European Heart Journal* 2021 [epub ahead of print]. PMID: 34423374

Publications- Peer-Reviewed: Silent Authorship

1. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. *New England Journal of Medicine* 1997;337:1118-1123. PMID: 9340503
2. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. *Lancet* 1998;352:87-92. PMID: 9672272
3. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. *Journal of the American College of Cardiology* 1998;32:2003-2010. PMID: 9857885
4. The NICE 4 Investigators. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 Trials. *Journal of Invasive Cardiology* 2000;12:E14-E18. PMID: 11156724
5. The Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000;101:2788-2794. PMID: 10859283
6. The SYMPHONY Investigators. Comparison of sibrافiban with aspirin, or both for secondary prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrافiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY). *Lancet* 2000;355:337-345. PMID: 10665552
7. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrافiban, or both for secondary prevention after acute coronary syndromes. *Circulation* 2001;103:1727-1733. PMID: 11282902
8. The NICE 4 Investigators. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *Journal of Invasive Cardiology* 2001;13:272-278. PMID: 11287711
9. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. *Circulation* 2002;105:316-321. PMID: 11804986
10. The PRIME Investigators. Multi-center, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion In Myocardial Infarction Evolution (PRIME) Trial. *American Heart Journal* 2002;143:95-105. PMID: 11773918

11. The APEX-AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. *Journal of the American Medical Association* 2007;297:43-51. PMID: 17200474
12. Cannon CP; STRIVE Scientific Committee. Updated Strategies and therapies for reducing ischemic and vascular events (STRIVE) unstable angina/non-ST-elevation myocardial infarction critical pathway toolkit. *Critical Pathways in Cardiology* 2008;7:43-81. PMID: 18458666
13. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *Journal of the American Medical Association* 2008;299:1903-1913. PMID: 18430909
14. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA2°P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 Trial. *American Heart Journal* 2009;158:335-341.e3. PMID: 19699854
15. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) Trial: study design and rationale. *American Heart Journal* 2009;158:327-334.e4. PMID: 19699853
16. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Journal of the American College of Cardiology*. 2010;55:2614-2662. PMID: 20513610
17. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Journal of the American College of Cardiology* 2010;55:2663-2699. PMID: 20513611
18. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation task force on consensus documents. *Circulation* 2010;121:2462-2508. PMID: 20479157
19. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Circulation*. 2010;121:2509-2543. PMID: 20479158

20. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*. 2011;123:2434-2506. PMID: 21518977
21. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. *The New England Journal of Medicine* 2012;366:1404-1413. PMID: 22443427
22. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial. Third universal definition of myocardial infarction. *European Heart Journal* 2012;33:2551-2567. PMID: 22922414

Publications – Web Sites

1. Tan WS, **Moliterno DJ**. Acute coronary syndromes: unstable angina in non-Q wave MI. www.healthstream.com
2. **Moliterno DJ**. Contributing author to ACC Cardio. www.acc.org
3. **Moliterno DJ**. Acute Reactions from the AHA, 2003. www.atherothrombosis.org
4. **Moliterno DJ**. Knowing (and applying) our ABCs—online commentary of Mukherjee D, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. *Circulation* 2004;109:745-9. www.americanheart.org
5. **Moliterno DJ**. Platelet GP IIb/IIIa Inhibitors. www.interventionalfellowsinstitute.com
6. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP; co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. www.cardiosource.com
7. **Moliterno DJ**, Sketch M, Popma, Mukherjee D. Chief Editor and author or co-author of 6 modules in: “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program), published by American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions. www.cardiosource.com

Publications - Book Chapters

1. **Moliterno DJ**, Elliott JM, Topol EJ. Randomized trials of myocardial revascularization. In “Current Problems in Cardiology” edited by O'Rourke RA; Mosby-Year Book, Inc., Mar 1995;20(3):123-190. PMID: 7600846
2. **Moliterno DJ**, Topol EJ. Clinical evaluation of restenosis. Chapter 93 in “Atherosclerosis and Coronary Artery Disease” edited by Fuster V, Ross R, Topol EJ; Raven Press, New York, 1995, pp 1505-1526.
3. **Moliterno DJ**, Topol EJ. Restenosis following coronary intervention. Update 17 for “Textbook of Interventional Cardiology” edited by Topol EJ; W.B. Saunders Company, Philadelphia, 1995, pp 257-2722.
4. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Evaluation of stenosis severity: quantitative angiography, coronary flow reserve, and intravascular ultrasound. In “Strategic Approaches in Coronary Intervention” edited by Ellis SG, Holmes DA. Williams & Wilkins, Baltimore, 1995, pp 207-234.
5. **Moliterno DJ**, Topol EJ. Percutaneous versus surgical coronary revascularization. A summary of the RITA, CABRI, GABI, EAST, and BARI Trials. Update 23 for “Textbook of Interventional Cardiology” edited by Topol EJ; W. B. Saunders Company, Philadelphia, 1996, pp 335-344.
6. **Moliterno DJ**, Topol EJ. Thrombolysis in acute myocardial infarction. In “Cardiovascular Drug Therapy” edited by Mezznerli FH; W. B. Saunders Company, Philadelphia, 1996, pp 1430-1442.
7. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Intravascular ultrasound assessments in coronary interventions. In “Handbook of Cardiovascular Interventions” edited by Sigwart U; Churchill Livingstone, New York, 1996.
8. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 385-403.
9. Miller JM, Ohman EM, **Moliterno DJ**, Califf RM. Clinical evaluation of restenosis. In “Textbook of Interventional Cardiology” 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1998, pp 379-415.
10. **Moliterno DJ**, Cohen M. Unstable angina. In “Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology” edited by Verstraete M, Fuster V, Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 439-460.
11. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: the pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 67-103.
12. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Comprehensive Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2397-2432.
13. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Textbook of Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2065-2100.

14. Steinhubl SR, **Moliterno DJ**. Antiplatelet and anticoagulant therapy in the prevention of ischemic heart disease. In "Preventative Cardiology" edited by Robinson R; Futura Publishing Co. Inc., Armonk, NY, 1998, pp 355-382.
15. **Moliterno DJ**. Anticoagulants in the treatment of acute coronary syndromes. In "Textbook of Interventional Cardiology" 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1999, pp 25-51.
16. **Moliterno DJ**, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" edited by Lincoff AM, Topol EJ. Humana Press, Inc., Totowa, New Jersey 1999, pp 201-227.
17. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 541-562.
18. Kapadia SR, **Moliterno DJ**. Section II editors: Chronic ischemic syndromes. In "Manual of Cardiovascular Medicine" edited by Marso SP, Griffin BP, Topol EJ; Lippincott Williams & Wilkins, New York, 2000, pp 69-96.
19. **Moliterno DJ**. Anticoagulants. In "CathSAP II" edited by Nissen SE; American College of Cardiology; Bethesda, 2000, pp 23-30.
20. **Moliterno DJ**. Care after myocardial infarction. Section in "Conn's Current Therapy 2000" edited by RE Rakel; W.B. Saunders Co., Philadelphia, 2000, pp 328-333.
21. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: The Pathophysiologic and Clinical Spectrum. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, NY, 2000, pp 135-172.
22. Mukherjee DB, **Moliterno DJ**. Bedside platelet monitoring. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 563-597.
23. Chan AW, **Moliterno DJ**. Restenosis: the clinical issues. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2002, pp 415-453.
24. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In "Textbook of Cardiovascular Medicine" 2nd ed. edited by Topol EJ; Williams & Wilkins Publishers, Philadelphia, 2002, pp 1715-1750.
25. **Moliterno DJ**. Anticoagulants and their use in acute coronary syndromes and coronary interventions. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2003, pp 33-64.
26. **Moliterno DJ**. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" 2nd ed. edited by Lincoff AM, Topol EJ. Humana Press Inc., Totowa, NJ, 2003, pp 233-262.
27. Chan AW, **Moliterno DJ**. Clinical evaluation of restenosis. In "Atherothrombosis and Coronary Artery Disease" 2nd ed. edited Fuster V, Topol EJ, Nabel EG; Raven Press, New York, 2004.

28. Quinn MJ, **Moliterno DJ**. Anticoagulation trials in acute coronary syndromes. In “A Comprehensive Handheld-Based Approach to CardioVascular Medicine” edited by Roffi M, Meier B, Topol EJ; CVMstat®, Handheldmed, Inc., Little Rock, AR, 2004.
29. Mukherjee D, **Moliterno DJ**. Bedside platelet monitoring. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 481-506.
30. Mukherjee D, **Moliterno DJ**. Monitoring anticoagulants in the catheterization laboratory and in the ICU when using combination therapies. In “Clinical, Interventional, and Investigational Thrombocardiology (Fundamental and Clinical Cardiology)” edited by Becker RC, Harrington RA, Marcel Dekker Publications, 2005.
31. Saw J, **Moliterno DJ**. Antiplatelet agents. In “Platelet Function: Assessment, Diagnosis and Treatment” edited by Quinn MJ, Fitzgerald D; Humana Press, Inc., Totowa, NJ, 2005, pp 335-367.
32. Saw J, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 457-480.
33. Saw J, **Moliterno DJ**. Differences between unstable angina and acute myocardial infarction: pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 129-156.
34. Saw J, **Moliterno DJ**. The rebirth of interest in pharmacoinvasive therapy in the stent era. In “Pharmacoinvasive Therapy in Acute Myocardial Infarction” edited by Sobel B, Dauerman H; Taylor & Francis, New York, 2005, pp 131-148.
35. Brown B, **Moliterno DJ**. Glycoprotein IIb/IIIa inhibitors – status 2005. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, De Caterina R, **Moliterno DJ**; Clinical Publishing, Oxford, 2006, pp 37-60.
36. Hamdalla H, **Moliterno DJ**. Procedures and management: multivessel angioplasty. Chapter 14 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 147-156.
37. Marshall JJ, **Moliterno DJ**. Pharmacology and ionotropes, antiarrhythmics, sedatives, and lipid-lowering agents. Chapter 6 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 41-48.
38. **Moliterno DJ**. Antiplatelet, antithrombotic, and thrombolytic agents. Chapter 5 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 32-40.
39. **Moliterno DJ**, Cho L, Mukherjee D. Primary, rescue, and facilitated angioplasty. Chapter 11 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Philadelphia, 2006, pp 88-96.
40. Morrison DA, **Moliterno DJ**, Vetrovec GW. Approach to coronary artery disease: medical therapy (including risk-factor modification), coronary artery bypass graft surgery, and percutaneous coronary intervention including complex PCI. Chapter 19 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 189-201.

41. Saraff K, Mukherjee D, **Moliterno DJ**. Monitoring of antithrombotic drugs. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, et al. Clinical Publishing, Oxford, 2006, pp 359-383.
42. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP, co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. www.cardiosource.com
43. Bhatheja R, **Moliterno DJ**. The interrelationship of thrombin and platelets—the protease-activated Receptor-1. Chapter 30 in “New Therapeutic Agents in Thrombosis and Thrombolysis” edited by Freedman JE, Loscalzo J; Informa Healthcare, USA, 2008, pp 517-533.
44. Falluji N, **Moliterno DJ**. Restenosis and in-stent restenosis. In “Essential Interventional Cardiology” 2nd ed. edited by Norell MS, Perrins EJ, Meier B, Lincoff AM; Saunders, Philadelphia, 2008, pp 151-161.
45. Hamdalla H, **Moliterno DJ**. Multivessel coronary artery disease. Chapter 9.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
46. Jozic J, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa receptor antagonists: fundamental and pharmacological aspects. Chapter 12 in “Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease” edited by Angiolillo DJ, Kastrati A, Simon DI; Informa Healthcare, USA, 2008, pp 101-105.
47. Macaulay T, **Moliterno DJ**. Vasopressors, ionotropes, and vasodilators. Chapter 6.8 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
48. **Moliterno DJ**. Platelet glycoprotein IIb/IIIa inhibitors. Chapter 6.2 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
49. **Moliterno DJ**. Restenosis. Chapter 2.6 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
50. Mukherjee D, **Moliterno DJ**. Chronic total Occlusions. Chapter 9.1 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
51. Mukherjee D, **Moliterno DJ**. Heparin-induced thrombocytopenia. Chapter 2.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.

52. Mukherjee D, **Moliterno DJ**. Hypercoaguable disorders. Chapter 2.4 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
53. Dawson CB, Mukherjee D, **Moliterno DJ**. High dose tirofiban. Chapter 19 in “Pharmacology in the Catheterization Laboratory” edited by Waksman R, Ajani A; Blackwell Publishing, Oxford, 2009, pp 154-157.
54. Falluji N, **Moliterno DJ**, Mukherjee D. Rescue coronary intervention for failed thrombolysis. Chapter 7 in “Primary Angioplasty in Acute Myocardial Infarction” edited by Tcheng, JE; Humana Press, Inc., Totowa, New Jersey, 2009, pp 101-114.
55. Dosh KM, **Moliterno DJ**. Glycoprotein IIb/IIIa Inhibitors. Chapter 8 in “Mechanical Reperfusion for STEMI: From Randomized Trial to Clinical Practice” edited by DeLuca G, Lansky A; Informa Healthcare USA, New York, New York, 2009, pp 83-93.
56. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, **Moliterno DJ**; Informa Healthcare, London, 2010, pp 53-66.
57. Gurley J, **Moliterno DJ**. Radiation Safety, Equipment, and Basic Concepts. Chapter 3 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 23-37.
58. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 50-59.
59. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 69-76.
60. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, Moliterno DJ; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 77-84.
61. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y₁₂ Inhibitors: Thienopyridines, Chapter 3 in “Therapeutic Advances in Thrombosis, 2nd edition” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 26-46.
62. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y₁₂ Inhibitors: Nonthienopyridines, Chapter 4 in 7 “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 47-61.

63. Wiisanen ME, **Moliterno DJ**. Interrelationship of Thrombin and Platelets: The Protease Activated Receptor-1. Chapter 7 in “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 71-86.
64. **Moliterno DJ**. Hemostasis, Platelet Biology, and the Coagulation Cascade. Chapter 1.3 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
65. Anaya P, **Moliterno DJ**. Hypercoaguable Disorders. Chapter 2.4 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
66. **Moliterno DJ**. Heparin-Induced Thrombocytopenia. Chapter 6.6 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
67. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, Lange RA, **Moliterno DJ**; Informa Healthcare, London, 2018, pp 71-88.
68. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 23-36.
69. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 68-75.
70. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 76-83.

Publications - Textbook Editor

1. Kristensen SD, De Caterina R, **Moliterno DJ**. Therapeutic Strategies in Thrombosis. Clinical Publishing, Oxford, 2005.
2. Mukherjee D, Cho L, **Moliterno DJ**. 900 Questions: An Interventional Cardiology Board Review. Lippincott Williams & Wilkins, Philadelphia, 2006.
3. **Moliterno DJ**. Editor-in-chief of CathSAP-3 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program). American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, Washington, DC, 2008.
4. Mukherjee D, Bates ER, Roffi M, **Moliterno DJ**. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease. Informa Healthcare, USA, London, 2010.
5. Mukherjee D, Cho L, **Moliterno DJ**. 1001 Questions: An Interventional Cardiology Board Review. Lippincott Williams & Wilkins, Baltimore, 2012.
6. **Moliterno DJ**, Kristensen SD, De Caterina R. Therapeutic Advances in Thrombosis, 2nd Edition. Wiley-Blackwell, London, 2012.
7. **Moliterno DJ**. Editor-in-chief of CathSAP-4 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program). American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, Washington, DC, 2012.
8. Mukherjee D, Bates ER, Roffi M, Lange RA, **Moliterno DJ**. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease, 2nd Edition. Informa Healthcare, USA, London, 2018.
9. Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Interventional Cardiology. 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition. Wolters Kluwer, New York, 2019.